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De mensen? Er bestaan er geloof ik zes of zeven. Die heb ik jaren geleden 
eens gezien. Maar je weet nooit waar je ze kunt vinden. De wind jaagt ze in 
het rond. Ze hebben geen wortels, dat is erg lastig voor ze. 
 











   
 






This vignette describes how a patient with schizophrenia can go through a long 
process of trying different medications, sometimes with benefits, but often 
experiencing life-influencing side effects (1). It also shows that CYP genotyping can 
provide additional treatment strategies, for example, lowering a dose of an 
effective antipsychotic drug.   
Patient M. is a 27-year-old man. Three years after he had to interrupt his high 
school education because of cognitive problems, he was diagnosed with 
schizophrenia. He was then 20 years old. At that time, he was single and 
working as a mailman. After being admitted to a psychiatric hospital because 
of screaming at night in the streets, he was prescribed haloperidol (4 mg/day) 
which had a good effect on his delusion of being poisoned. However, he 
developed parkinsonism, presenting as walking slowly without arm swing, 
rigidity, lack of facial expression and a monotonous voice. In the next 3 years, 
he switched to risperidone (4 mg/day), but the parkinsonism persisted although 
it was a little less than with haloperidol. However, he gained 10 kg in weight. 
He lost his job, changed his day and night rhythm, and started to isolate 
himself. These behaviors were indicated as negative symptoms as a sign of 
schizophrenia, which made him and his psychiatrist decide to switch to15 
mg/day of aripiprazole. The switch led to psychotic symptoms again and he 
had to be re-admitted to hospital. There he participated in a prevalence study 
on CYP enzymes, which revealed he was a poor metabolizer of CYP2D6 
(genotype CYP2D6 *4/*4). Because haloperidol, risperidone and aripiprazole 
are all metabolized by the CYP2D6 enzyme, for years he had been given 
relatively high dosages of antipsychotic medication to control his psychoses. 
Based on the Dutch KNMP guideline, 2 mg/day of haloperidol was then 
prescribed, which effectively reduced his psychotic delusions. He did not develop 
any parkinsonism and was clearly more active. His earlier negative symptoms 
were now interpreted as secondary negative symptoms caused by the relatively 
high dosage of haloperidol or risperidone. 
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Prescribing antidepressant or antipsychotic medication in psychiatry can be a difficult 
process, in which possible benefits have to be carefully weighed against frequently 
occurring side effects. Medication history, age, physical parameters, and other 
variables are considered in the process of deciding on the appropriate medication. 
However, strong personalized predictors that could guide the pharmacotherapy are 
often lacking. Thus, many patients experience the search for the most appropriate 
medication as a process of trial and error. Genetic factors may play a major role in a 
drug’s effectivity and side effects. It is estimated that one-quarter of the variability in 
drug response is due to an individual’s genotype (2). Of specific interest are the 
activity of the CYP2D6 and CYP2C19 enzymes because 50-75% of all antidepressant 
and antipsychotic drugs are metabolized by one of these two enzymes 
(https:/www.gipdatabank.nl/servicepagina/open-data) (3,4). Multiple studies show 
that the activity of the CYP2D6 and CYP2C19 enzymes is related to the prevalence of 
side effects and to treatment response (5–7). 
What would happen if we were to choose and optimize the dose of psychiatric 
medication according to a CYP genetic profile? 
Studies on the Caribbean island of Curaçao show there is a relatively high prevalence 
of drug-induced movement disorders, such as parkinsonism, tardive dyskinesia, and 
especially tardive dystonia, in patients with mental disorders (8). A large percentage 
of the population also suffers from metabolic syndrome (9), and in some 
subpopulations in the Caribbean region, the prevalence of poor metabolizers of 
CYP2D6 is extremely high (~10%) (10).  
Until now, we did not know what the prevalence of non-normal CYP metabolizers 
was in this island population. In European populations, the prevalence of slow and 
ultrarapid metabolizers is 5% and 3%, respectively (11). Knowing the prevalence of 
non-normal CYP metabolizers in the island’s population is of major clinical 
importance, especially if there is a clear relationship between the prevalence of non-
normal metabolizers and the occurrence of side effects and treatment resistance. 
Genotyping could offer the possibility of preventing side effects by indicating a 
different type of antipsychotic or antidepressant medication, or a different dose, 
according to an individual’s genetic profile. A better response to prescribed 
medication would improve daily functioning and quality of life. Given these major 
benefits, the cost of genotyping will be worthwhile. 
In this thesis I investigate whether CYP genotyping improves treatment outcomes in 
psychiatric patients. First, I provide a systematic review and meta-analysis to report 
a worldwide epidemiological perspective. Thereafter, I will focus on patients with 







There is tremendous variation in the speed at which individuals metabolize 
medication into inactive compounds in the liver. The effect of most medication is 
determined by the rate at which it is metabolized.  
The so-called ‘phase I reaction’ by the cytochrome P450 (CYP) is responsible for the 
metabolization of lipophilic medication into more hydrophilic compounds, which are 
then excreted via the kidneys (12,13). There are many factors influencing the speed 
at which the CYP450 metabolizes, for example, diet, medication, alcohol, drugs, 
smoking, pregnancy and age (14–19). 
However, one of the most important factors is an individual’s combination of genetic 
variants or alleles (denoted by *). These alleles can be determined by collecting blood 
or specimens and detecting insertions, deletions, and gene rearrangements in their 
DNA.  
Depending on the number of functional alleles, genotypes can be translated into a 
predicted phenotype. In ascending metabolization rate, they can be divided into 
poor metabolizers (PM), intermediate metabolizers (IM), normal metabolizers (NM, 
also referred to as extensive metabolizers EM) and ultrarapid metabolizers (UM). 
Because the serum level of medication is related to the activity of the enzyme, which 
is partly determined by the individual genotype, the same dosage will lead to a 
higher serum level in PMs and IMs than in NMs, and to a lower serum level in UMs 
than NMs (Figure 1). The serum level is often related to the effectivity of the drug 
and to the risk of dose-related side effects (20–25).  
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Figure 1.   Schematic adaptation of doses due to genotypes causing  
differences in drug metabolism and elimination (26). 
 
PM=poor metabolizer, IM=intermediate metabolizer,  
NM/EM=normal/extensive metabolizer, UM=ultrarapid metabolizer 
c=concentration of drugs in blood, t=time in hours 
 
 
There are eight gene families (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, 
CYP2E1 and CYP3A4) relevant to pharmacotherapy; each is responsible for the 
metabolism of a different group of medications. Most medication is mainly 
metabolized by one enzyme, but the process can be taken over by other enzymes if 
a certain enzyme is not functioning or is occupied with the metabolization of other 
biochemicals.  
The CYP2D6 and CYP2C19 enzymes are specifically relevant to the metabolism of 
psychiatric drugs (27–32). Both genes are highly polymorphic, which means that 
there are many allelic variants accounting for the enzyme’s functionality. So far, more 
than 100 variants of the CYP2D6 gene and more than 50 variants of the CYP2C19 
gene have been identified. Each allelic variant has its own properties and the 
functionality of the CYP2D6 and CYP2C19 alleles are listed in PharmVar 
(https://www.pharmvar.org/gene). The combination of alleles is translated into a 




Table 1.  Allele combinations of CYP2D6 leading to predicted phenotypes1 
 
Allele *1 *2 *3,  *4 *5 *6 *7 *8 *9 *10 *17 *29 *41 
*1 NM NM IM IM IM IM IM IM NM NM NM NM NM 
*2  NM IM IM IM IM IM IM NM NM NM NM NM 
*3   PM PM PM PM PM PM IM IM IM IM IM 
*4    PM PM PM PM PM IM IM IM IM IM 
*5     PM PM PM PM IM IM IM IM IM 
*6      PM PM PM IM IM IM IM IM 
*7       PM PM IM IM IM IM IM 
*8        PM IM IM IM IM IM 
*9         IM IM IM IM IM 
*10          IM IM IM IM 
*17           IM IM IM 
*29            IM IM 
*41             IM 
 
PM=poor metabolizer, IM=intermediate metabolizer, NM=normal metabolizer,  
UM=ultrarapid metabolizer 
1 The CYP2D6 UM variant is a result of 1 to 10 gene duplications 
 
 
Table 2.  Allele combinations of CYP2C19 leading to predicted phenotypes 
Allele *1 *2 *3 *17 
*1 NM IM IM UM 
*2  PM PM IM 
*3   PM IM 
*17    UM 
 
PM=poor metabolizer, IM=intermediate metabolizer, NM=normal metabolizer, 
UM=ultrarapid metabolizer 
  




When prescribing medication metabolized by CYP2D6 or CYP2C19 enzymes, drug 
interactions must also be considered. There are two possibilities by which co-
medication (medication taken at the same time) can influence the speed at which the 
enzyme metabolizes. Inhibiting medication competes with the substrate drugs or 
inactivates the metabolizing enzyme and thus lowers the level of metabolism of the 
substrate drug, which can result in toxic serum levels. Inducing medication increases 
the rate of metabolization by the enzyme, which can result in sub-therapeutic serum 
levels. One important combination seen in psychiatry is a prescription for 
omeprazole (for reducing stomach acid), which inhibits the CYP2C19 activity, with a 
selective serotonin reuptake inhibitor (SSRI), which is metabolized by the CYP2C19 
enzyme (e.g. escitalopram, citalopram and sertraline. Another common combination 
is that of a CYP2D6-inhibiting antidepressant (e.g. fluoxetine or bupropion) 
prescribed with an antipsychotic which is metabolized by the CYP2D6 enzyme (e.g. 
aripiprazole or risperidone). 
 
CYP2D6 
In 1988 CYP2D6 was determined to be the enzyme responsible for inter-individual 
differences in response to debrisoquine (an antihypertensive drug) and sparteine (an 
antiarrhythmic) (35). Later, it was discovered that this enzyme was metabolizing 20% 
of all medication prescribed (36). It was mapped to the 22q13.1 chromosome and 
the first genetic variations were reported in 1990 (37,38). Medications metabolized 
by CYP2D6 include first- and second-generation antipsychotics, SSRIs, and tricyclic 
antidepressants (TCA) (Table 3). See also https://cpicpgx.org/genes-drugs.  
In patients with schizophrenia, drug-induced movement disorders are a major side 
effect of antipsychotic medication. These disorders can be divided into acute 
(starting shortly after taking a dopamine-blocking agent) and tardive (arising months 
to years after using dopamine-blocking agents) syndromes. The most important 
acute syndromes are parkinsonism, akathisia and acute dystonia, while the tardive 
syndromes are tardive dyskinesia and tardive dystonia. Because of the symptoms’ 
visibility and the impaired movement control, these medications are linked to great 
impairment and poorer treatment adherence (39). Drug-induced movement 
disorders are often dose-dependent and occur above a certain level (78%) of 
dopamine D2 receptor occupancy (40,41). They are found to be more prevalent in 
PMs and IMs. However, clinical response to antipsychotic medication is significantly 
increased if D2 occupancy exceeds 65% (41), and UMs only benefit from higher doses 




A meta-analysis of patients with schizophrenia has shown an increased risk of drug-
induced tardive dyskinesia and parkinsonism in patients with a non-NM genotype 
on typical antipsychotic medication (6). The costs of treatment and length of 
hospitalizations of PMs and UMs are, on average, longer than for IMs and NMs (5,42). 
In another cost analysis of patients with schizophrenia in Denmark, it was found that 
total health costs among all extreme metabolizers (PM+UM) were 177% higher than 
among the NMs, and that genotyping could lead to lower treatment costs (7). 
Recently, a study of patients with schizophrenia showed that those who had 
pharmacogenetic testing prior to a switch or to start of antipsychotics showed less 
side effects than patients receiving treatment as usual, even though the effects were 
minimal and not significant (43). The Pharmacogenetics Working Group guidelines 
from the Royal Dutch Association for the Advancement of Pharmacy recommend 
genotype-guided dose adjustments for patients with a non-normal CYP2D6 
genotype, and use of haloperidol, risperidone, aripiprazole and zuclopenthixol (44).  
TCAs have a narrow therapeutic window to reach maximal efficiency and a minimum 
number of side effects. Optimal plasma concentrations have been defined for their 
use. PMs and IMs are thought to be more vulnerable for side effects and treatment 
failure than NMs. Although there is limited evidence of the benefits of genotyping 
on efficacy and toxicity, clinical guidelines recommend dose adjustments in patients 
on SSRIs or TCAs with non-NM genotypes (45–47). 
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Table 3.  Antidepressant and antipsychotic medication metabolized  



















































# Table 3 is based on information from the PharmKGB Clinical Guideline Annotations, 
consulted 5 November 2020. See also https://www.pharmgkb.org/ 






Medications metabolized by CYP2C19 include SSRIs and TCAs (Table 3) The gene 
was mapped to the 10q24 chromosome and the first genetic variations were 
reported in 1995 (48). Multiple studies have shown a relationship between the 
CYP2C19 genotype and plasma concentrations of TCAs; extreme metabolizers have 
increased risk for side effects and treatment failure (49–52). Treatment effects of 
SSRIs are less dose-dependent than for antipsychotics and there is conflicting 
evidence on the influence of CYP2C19 on response and toxicity (53). Nonetheless, a 
few studies show an overall improvement of depressive symptoms in patients on 
genotype-guided treatment (54–56). 
 
Curaçao 
Both CYP2D6 and CYP2C19 genes are highly polymorphic and the prevalence of the 
different CYP alleles varies widely across ethnic groups (57). It is speculated that 
because CYP2D6 has a high affinity with alkaloids, it may have played a role in 
detoxification when people had to eat toxic plants during periods of starvation. It is 
thought that selection pressure favored survival of ultrarapid metabolizers in, for 
example, Ethiopia, where the population expanded rapidly between 10,000–20,000 
years ago (58). Research into CYP enzymes in Latin America also shows large inter-
ethnic differences, with the prevalence of CYP2D6 PM varying from 0-10.2% (10). 
Until now, the prevalence of CYP2D6 and CYP2C19 in the group of Caribbean islands 
that made up the former Netherlands Antilles was not known (59). The population of 
Curaçao originated from Western Africa and has admixed with European immigrants 
and Native South Americans (60). Together with Aruba and Bonaire, Curacao forms 
the ‘ABC’ islands. Until 2010, these islands (together with St Maarten, Saba and St. 
Eustatius) formed the Netherlands Antilles. Curaçao is one of the western Leeward 
Antilles in the Caribbean and the island now has about 156,223 inhabitants (61). In 
January 2020, there are some 166,265 immigrants (first- and second generation) 
from the former Netherlands Antilles living in the Netherlands (62). This group, and 
particularly the second-generation immigrants, has a high risk of developing 
psychotic disorders and are more often retained for compulsory admission to a 
psychiatric hospital (63,64).  
The healthcare system on Curaçao is based on the Dutch healthcare system. All 
inhabitants have access to high standard healthcare and have medical insurance 
coverage. However, the Caribbean lifestyle is characterized by sedentary behavior 
and an unhealthy diet, so that obesity and metabolic syndrome are both widespread 
problems. The whole Caribbean region is currently suffering from an obesity and 
diabetes epidemic (9). De Caluwe has recently shown that especially female 
Chapter 1  
22 
 
Caribbean patients with severe mental illness (SMI) are at risk for metabolic 
syndrome, with a prevalence of 63.6% vs. 33.1% in other ethnicities (9). A high 
prevalence of dose-dependent movement disorders, especially dystonia, was also 
found by a naturalistic cohort study in an 18-year follow-up of patients with 
schizophrenia on Curaçao (8,65,66). If the prevalence of slow or rapid metabolizers 
in this population is related to their side effects and treatment resistance, it would 
be a clinically important factor. We therefore wanted to determine if the prevalence 
of poor-, intermediate- and ultrarapid metabolizers is different than in European 
populations, for example. Since some studies have also shown a correlation between 
CYP activity and the occurrence of schizophrenia (67), we decided to investigate if 
CYP prevalence differs between the Antillean population with and without psychiatric 
disorders. We studied both populations on the island of Curaçao, but also collected 
DNA samples from sputum of immigrants from the former Netherlands Antilles at 
events they held in the Netherlands. To evaluate the health benefit to general 
practice, we have sent our genotyping results to general practitioners in the 
Netherlands.  
 
Severe mental illness and measures of functioning 
Patients with severe mental illnesses (SMI) are known to suffer particularly from side 
effects and poor medication response (1,68–70). A study in 1827 patients showed 
that over 90% reported at least one drug-induced side effect and high levels of 
distress (1). When patients suffer from one movement disorder, the chances of 
developing a second or third movement disorder are increased (71). These side 
effects impair their psychosocial functioning and quality of life (1). Genotyping in 
patients with SMI can help personalize treatment, and potentially reduce side effects 
and levels of distress in slower metabolizers; it can increase treatment effects in rapid 
metabolizers; and eventually lead to better psychosocial functioning and better 
quality of life (72). We therefore selected a group of 45 patients with SMI and a non-
normal metabolizer profile from Curaçao and adjusted their medication to better fit 
their CYP2D6 profile. We investigated if this intervention influenced their side effects, 
treatment response and daily functioning.  
The term ‘Severe Mental Illness’ was introduced by the USA Substance Abuse and 
Mental Health Services Administration to differentiate between psychiatric patients 
with and without problems in daily functioning (73). Central to the monitoring of 
their recovery process is the measurement of patients’ psychosocial functioning. This 
can be measured using the WHODAS 2.0 questionnaire, introduced in DSM-5. It has 
been validated across different cultures, and can measure function in six domains. 
Although the patient version has shown reliable clinical outcomes, there was limited 




population to see if it could parry problems with cognitive deficits and lack of disease 
insight, and whether it was useful for measuring disease outcomes (74–76). 
 
Outline of this thesis 
Although there is a wealth of information and clinical guidelines recommend 
genotype-guided dose adjustments, pharmacogenetics is still not widely used. The 
work in this thesis aimed to bridge the gap between the scientific evidence for 
pharmacogenetic testing and clinical psychiatric practice (77). 
In chapter 2 we review the literature on CYP2D6 and CYP2C19 genotypes worldwide. 
We included studies which fulfil criteria for use in clinical practice and estimated the 
probability of an individual having a non-NM metabolizer profile.  
In chapter 3 we describe how we determined the prevalence of CYP2D6 and 
CYP2C19 genotypes in patients with severe mental illnesses (SMI) and in volunteers 
from the general population in the former Netherlands Antilles. This meant we could 
analyze the data to detect differences in prevalence between patients with SMI and 
the general population.  
In chapter 4 we assess the clinical utility of CYP2D6 genotyping by prospectively 
investigating the influence of dose adjustments on psychiatric symptoms, side 
effects, and functioning in patients with SMI.  
In chapter 5 we describe how we measured the psychosocial functioning of patients 
with SMI and assess the relationship with their psychiatric symptoms, side effects, 
and quality of life. We used the (proxy) WHODAS 2.0 questionnaire, which was 
adopted by DSM-5.  
Finally, in the general discussion (chapter 6), our findings are placed in a broader 
perspective, focusing on arguments for and against genotyping in psychiatric 
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Extensive migration has led to the necessity of knowledge regarding the treatment 
of migrants with different ethnical backgrounds. This is especially relevant for 
pharmacological treatment, because of the significant variation between migrant 
groups in their capacity to metabolize drugs.  For psychiatric medications, CYP2D6 
and CYP2C19 enzymes are clinically relevant. The aim of this meta-analysis was to 
analyze studies reporting clinically useful information regarding CYP2D6 and 
CYP2C19 genotype frequencies, across populations and ethnic groups worldwide. To 
that end, we conducted a comprehensive meta-analysis using Embase, PubMed, 
Web of Science and PsycINFO (>336 000 subjects, 318 reports). A non-normal 
metabolizer (non-NM) probability estimate was introduced as the equivalent of the 
sum-prevalence of predicted poor, intermediate and ultrarapid metabolizer CYP2D6 
and CYP2C19 phenotypes. The probability of having a CYP2D6 non-NM predicted 
phenotype was highest in Algeria (61%) and lowest in Gambia (2.7%) while the 
probability for CYP2C19 was highest in India (80%) and lowest in countries in the 
Americas, particularly Mexico (32%). The mean total probability estimates of having 
a non-NM predicted phenotype worldwide were 36.4% and 61.9% for CYP2D6 and 
CYP2C19, respectively.  
We provide detailed tables and world maps summarizing clinically relevant data 
regarding the prevalence of CYP2D6 and CYP2C19 predicted phenotypes and 
demonstrating large inter-ethnic differences. Based on the documented probability 
estimates, pre-emptive pharmacogenetic testing is encouraged for every patient 
who will undergo therapy with a drug(s) that is metabolized by CYP2D6 and/or 
CYP2C19 pathways, and should be considered in case of treatment resistance or 
serious side effects.   
 




Migration is a growing global phenomenon so that Western-trained psychiatrists are 
increasingly treating migrants with different cultural and ethnic backgrounds(78). In 
the psychopharmacological treatment of migrants, variation in drug metabolism is 
an important aspect that must be taken into account (79). In psychiatry, CYP2D6 and 
CYP2C19 are important drug metabolizing enzymes (27–32). For example, drugs that 
are metabolized by CYP2D6 include first and second generation antipsychotics, 
selective serotonin receptor inhibitors, and tricyclic antidepressants (29). Among 
those metabolized by CYP2C19 are benzodiazepines, selective serotonin receptor 
inhibitors, and tricyclic antidepressants (29). Individuals’ genetic variation is the most 
important factor influencing the kinetics of drug metabolism, and thus may 
contribute to intolerability-related discontinuation or treatment failure (80). 
The outcome of a pharmacogenetic test (i.e. a patient’s genotype, sometimes also 
referred to as diplotype) can be translated into a predicted phenotype. A 
combination of functional and non-functional alleles are responsible for the activity 
of the enzymes. There are four phenotype groups: poor (PM), intermediate (IM), 
normal (NM) (previously referred to as ‘extensive’), and ultrarapid metabolizers (UM), 
which are used to predict whether and how well a drug is metabolized. The same 
drug dosage may lead to a higher plasma level in PMs and IMs, compared to NMs, 
because of slower drug clearance, while UMs may have lower plasma levels than NMs 
because of a higher rate of drug clearance. Plasma levels are often related to the 
efficacy of a drug and the risk of dose-related side effects, with more severe side 
effects found in PMs and IMs than NMs (20–25). 
The prevalence of CYP polymorphisms also varies considerably across ethnic groups 
and plays a major role in inter-individual and inter-ethnic differences in drug 
metabolism and response (57). For example, in European populations, just 2-3% of 
the population have a CYP2D6 UM profile, compared to 20-29% in East-African 
populations (11,81). In contrast, CYP2C19 PMs are considerably more frequent in 
Asians (~12%) than in Europeans (~2%) (82). Some allelic variants such as CYP2D6*40 
and *45 are only seen in specific populations (83,84). 
The Clinical Pharmacogenetics Implementation Consortium (CPIC) has published 
guidelines with recommendations for drug choice and dosage based on phenotype 
predictions (44,46,47,85). 
Other groups, including the Royal Dutch Association for the Advancement of 
Pharmacy – Pharmacogenetics Working Group (DPWG), have also published 
guidelines (information for both organizations is available through the 
Pharmacogenomics Knowledge Base at https://www.pharmgkb.org/guidelines). 
CYP2D6 and CYP2C19 allele frequency information has been compiled by CPIC and 




Fricke-Galindo et al and Llerena et al have described CYP2D6 and CYP2C19 
phenotype prediction from genotype across world populations (11,82,86).  
Although there is a wealth of information, pharmacogenetics is still not being widely 
used in clinical practice. Several studies have shown the relationship between CYP 
activity, blood serum levels, and side-effects, but there have been few studies on 
clinical effectivity. Most of the studies are cross-sectional and observational, while 
prospective studies are often underpowered (7,27,87,88). For some drugs, clinicians 
are used to working with therapeutic drug monitoring and they may prefer this over 
genotyping. 
Another reason is the lack of education of practitioners on this topic and the belief 
that pharmacogenetics “is not ready” for use in daily clinical practice (89–92). Despite 
these barriers, pharmacogenetics is increasingly being adopted by major health 
centers, and the body of literature in support of pharmacogenetic testing is growing 
(5,7,42,87,93–96). 
The aim of our meta-analysis was to assess studies reporting clinically useful 
information about CYP2D6 and CYP2C19 genotype frequencies across populations 
and ethnic groups worldwide. We introduce the concept of the non-normal 
metabolizer (non-NM) probability estimate, for which we calculated the sum-
prevalence of a population for having a poor, intermediate or ultrarapid CYP2D6 or 
CYP2C19 predicted phenotype. The sum-prevalence of these three predicted 
phenotypes presents a single measurement for non-normal metabolism in the 
populations of interest. It is defined as the equivalent of the prevalence of PM + IM 




For this study we followed the checklist in the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) statement (97,98). The protocol for 
the current systematic review was not registered prior to the review.  
Review of literature 
We conducted a literature review using the Embase, PubMed, Web of Science and 
PsycINFO databases (1990-2019). The terms ‘CYP2D6’ AND/OR ‘CYP2C19’ AND 
‘prevalence’ OR ‘ethnicity’ OR ‘race’ AND ‘healthy subject’ OR ‘normal control’, and 
variations on these terms and the names of different countries and continents were 
used in all fields. The last search was conducted on July 3rd, 2019. 
Worldwide variation of CYP2D6 and CYP2C19 
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Our inclusion criteria were: (1) CYP2D6 or CYP2C19 allele frequencies from original 
data were reported; (2) the evaluated subjects did not have a specific disease 
(controls from case-control studies were included); (3) ethnicity was reported; (4) the 
article was published in English; (5) a minimum of 20 participants was investigated. 
If only an abstract was available, the article was included if all the above information 
was available and (6) in order to be able to calculate a probability estimate, it was 
necessary to assess a minimum number of non-functional alleles and alleles with 
decreased function as well as a number of gene duplications. The genotyping assay 
included at least the following allelic variants: CYP2C19*2 and *17  in Africans, 
Americans, Europeans, Middle Easterners, Central/ South East-Asians and African 
Americans. CYP2C19*2, *3 and *17 in Oceanians and CYP2C19*2 and *3  in East 
Asians. CYP2D6*2, *5, *17, *29 and *41 in Africans. CYP2D6*2 and *4 in Americans. 
CYP2D6*2 and *10 in East Asians. CYP2D6*2, *4 and *41 in Europeans. CYP2D6*2, *4, 
*10 and *41 in Middle Easterners and Central/South East-Asians. CYP2D6*5 in 
Oceanians. CYP2D6*2, *4, *17 and *29 in African Americans.  
An eligibility assessment was performed independently in a standardized manner by 
A.K. and D.V. The first screening was based on the article abstracts; the next selection 
was based on the full text. Disagreements between the two reviewers were resolved 
by discussion to reach a consensus.  
 
Data extraction 
The data were independently extracted from the studies by two investigators (A.K. 
and P.B.) and randomly checked by two investigators (D.V. and A.K.). For some 
studies, authors were contacted for clarification of the data. 
Information was extracted from each study as follows: (1) ethnicity of the participants; 
(2) definition of ethnicity (self-reported or genetic ancestry); (3) country of the 
studied population; (4) number of study participants; (5) study design (prevalence 
study, case-control study, experimental study); (6) allele frequencies; (7) diplotype 
frequencies; (8) predicted phenotype frequencies.  
Star (*) alleles were assigned according to the Pharmacogenetic Variation (PharmVar) 
Consortium at https://www.pharmvar.org (99,100).  
  
Ethnicity and Geographical regions 
To be able to compare outcomes with previous meta-analyses, reported ethnicity 
was assigned to geographic regions, as done in previous meta-analysis about this 




regions were considered: Africa, Americas (including Latino Americans and 
indigenous inhabitants of North America and Canada), East Asia, Europe (including 
North Americans and Canadians), the Middle East, Oceania and Central/Southeast 
Asia; with one exception, namely that African-Americans were listed separately from 
Africans (11). Here, the frequencies of PM, IM, EM, and UM are reported by ethnicity, 
whereas the probability estimates of being a non-normal metabolizer are reported 
by country. In many studies, these two factors –country and ethnicity– overlap, but 
for some studies we had to assign an ethnicity to a country to be able to show the 
information in world maps (i.e. the two factors were not distinguished). The origin of 
the investigated ethnicity determined the country and region to which a population 
was assigned. An exception was made for Latin America, in which the population is 
an admixture of multiple origins (e.g. European, African, Asian and Amerindian) and 
no clear lineages can be determined; they were all considered as populations of the 
Americas and determined as belonging to the country they live in (102,103). For 
some ethnicities we could not determine a country of origin (for example, East Asians 
or Europeans) so we have indicated them as ‘missing’ in the figures. 
 
Translation of genotype into phenotype 
For each geographical region, the mean frequency of alleles was determined. In order 
to predict CYP2D6 and CYP2C19 phenotype frequencies from genotype data we 
applied the activity score (AS) system to both genes (the AS system is widely used 
for CYP2D6 and was adapted to CYP2C19 to facilitate the translation process) (33). 
Briefly, a normal function allele was valued as 1, decreased function alleles as 0.25 or 
0.5, a non-functional allele as 0, and increased function allele as 1.5. Gene 
duplications received double the value of their singleton counterparts. Homozygous 
carriers of non-functional alleles were classified as PMs (AS = 0). Carriers with one 
functional or decreased function allele and one non-functional allele, and those 
carrying two decreased function alleles were classified as IMs (AS = 0.25-1) (33). 
Homozygous carriers of normal function alleles, and heterozygous carriers with one 
decreased function and one normal function allele, were classified as NMs (AS = 
1.25-2.25) (33). Carriers of one or more increased function alleles, and carriers of a 
duplication or multiplication of a functional allele, were classified as UMs (AS >2.25) 
(33) (https://cpicpgx.org/resources/term-standardization/). CYP2C19 rapid and 
ultrarapid metabolizers were pooled and analyzed as UMs. The functionality of the 
CYP2D6 and CYP2C19 alleles was classified as listed by PharmVar in Table 1.  
In this meta-analysis, we applied strict criteria. To maximize the accuracy of the 
frequencies of the predicted phenotypes, we only predicted a phenotype if the 
original publication reported a minimum of non-/decreased function alleles and the 
assays included tests for gene duplications. Since the prevalence of alleles differed 
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greatly per region, we used criteria specific for each geographical region. Alleles 
more prevalent than 0.05 (5%) in the major region (Table 2) had to be investigated 
in the countries within that region to be included in the phenotype predictions.  
 
Table 1.  Functionality of CYP2D6 and CYP2C19 alleles (https://www.pharmvar.org/gene) 
 
 CYP2D6 CYP2C19 
0 *3-*8, *15, *18, *31, *36, *47, 
*51, *56, *57, *62, *92, *100 and 
*101 
*2, *3, *4, *5, *6, *7, *8, *23 and 
*24 
0.25-0.5 *9, *10, *17, *29, *41, *49, *50, 
*54, *55, *59 and *72 
*9, *10, *12, *16, *25 and *27   
1 *1, *2, *27, *39, *45, *46 and 
*48 
*1, *13, *15 and *18   
1.5 *53 *17 





Calculations and statistics 
All analyses were performed with IBM SPSS Statistics Version 25. If only diplotypes 
were reported, single allele frequencies were calculated. If only single allele 
frequencies were reported, diplotype frequencies were calculated using the Hardy 
Weinberg Equilibrium (HWE) (p² + 2pq + q² = 1). For studies that did not report the 
prevalence of CYP2D6*1, the allele frequency was calculated as 100% minus the sum 
of variants(11). The diplotypes were translated into predicted phenotypes according 
to the CPIC.  
We introduce here the concept of the non-normal metabolizer (non-NM) probability 
estimate. It is defined as the sum of the prevalence of PM + IM + UM predicted 
phenotypes of the enzymes CYP2D6 or CYP2C19 in percentages. Thus, it is equivalent 
to the prevalence (as percentage) of all the non-normal phenotypes in a population. 
We use the term probability estimate exclusively in this sense and it is in fact a 
proportion of the possible outcomes in a population. It is equal to 100% minus the 
% of NM in a given population. 
The studies were weighted by sample size (number of participants) when we 





Of the 2873 publications retrieved from the database 318 original research papers 
met our inclusion criteria (Figure 1.). The analyses of CYP2D6 (n=200 papers) and 
CYP2C19 (n=159 papers) included 261 296 and 257 745 healthy individuals. The 
alleles most frequently investigated were CYP2D6 *1-*6, *10, *17 and CYP2C19 *1-
*3. Allele frequencies are shown per major geographical region in Table 2. The most 
frequently observed variant alleles across all subjects were CYP2D6*2, *4, *10 and 
*41, and CYP2C19*2 and *17. As expected, allele frequencies varied substantially 
among ethnicities and countries. We found 89 studies that reported on more than 
one ethnic group. Overall, African and Middle Eastern countries were 
underrepresented, while European populations were the most frequently 
investigated.  
 
Figure 1. Flow diagram of the studies included in the analyses
 









Prevalence of predicted phenotypes by ethnicity 
Predicted phenotype was reported or could be inferred from 51 studies for 116 
ethnicities, covering n=194 714 individuals. These studies were selected for fulfilling 
the minimum number of alleles tested as prescribed by our region-specific criteria. 
Due to the high frequency of allele duplications, high percentages of CYP2D6 UM 
were found in the Mozabite people, a Berber ethnic group in the Sahara, North Africa 
(39.5%)(104); in non-Austronesian Melanesians (21.5%) (104), and in the ethno-
religious Druze from the Middle East (21.4%) (104). High percentages of CYP2D6 PM 
were found in Europeans, for example in the British (12.1%) (105), the Danish 
(10.6%)(106) and Basque (French) people (9.7%) (104) due to the high frequency of 
CYP2D6*4. Frequencies of CYP2D6 predicted phenotypes by ethnicity are 
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Probability estimates by country 
The probability of having a CYP2D6 non-NM predicted phenotype is the highest in 
Algeria (non-NM probability estimated to be 61.2%) (*4, *17, *41 and 
duplications)(104), Argentina (non-NM probability estimate 51.4%) (*4, *41 and 
duplications)(10), and France (non-NM probability estimate 50.4%) (*4, *5, *41 and 
duplications)(104). The CYP2D6 non-NM probability estimate was lowest in several 
populations from Africa (Gambia 2.7%, Kenya 4.0% and Sierra Leone 5.9%) and 
South-East Asia (Vietnam 5.1%, Sri Lanka 7.8%) (105). See Figure 2 for CYP2D6 non-
NM probability estimates and Figure 3 for CYP2D6 non-NM probability estimates 














Prevalence of predicted phenotypes by ethnicity 
Data were retrieved from 73 studies describing 225 173 subjects of 85 ethnic 
groups/countries. These studies were selected for fulfilling the minimum number of 
alleles tested as prescribed by our region-specific criteria. The UM predicted 
phenotype is rather common in Ecuadorian Mestizos (41.4%) (107), Dargins (39.8%) 
(108), and ethnic groups living in the North Caucasus in Russia, and in Burushu, 
Pakistan (39.0%) (109,110) owing to a high prevalence of over 20% of CYP2C19*17 
in all these populations. High percentages of CYP2C19 PMs were found in Indian and 
Pakistani populations (Naik 31.0% (111) and Saraiki 20.0% (110)), Tohoku Japanese 
(18.9%) (112),and in Chinese Hui (28.0%) (113,114) due to the presence of the 
CYP2C19*2 and *3 non-functional alleles. Table 4 summarizes the frequencies of 














Probability estimates by country 
The probability of having a CYP2C19 non-NM predicted phenotype due to high 
frequencies of the non-functional CYP2C19*2 allele and/or the increased function 
CYP2C19*17 allele is highest in India (non-NM probability estimate 80.1%) 
(111,115,116), Pakistan (non-NM probability estimate 74.8%) (110,117,118), and Iran 
(non-NM probability estimate 69.2%)(119,120). The probability is lowest in countries 
in the Americas, particularly Mexico (non-NM probability estimate 31.7%) (121–123) 
and Costa Rica (non-NM probability estimate 33.9%) (124). CYP2C19 non-NM 
probability estimates are shown in Figure 4 and Figure 5 displays CYP2C19 non-NM 













In this meta-analysis we introduce a clinical useful concept of a non-normal 
metabolizer (non-NM) probability estimate as the equivalent of the sum-prevalence 
(in percentages) of PM + IM + UM predicted CYP2D6 and CYP2C19 phenotypes. The 
mean totals of non-NM probability estimates worldwide were 36.4% (CYP2D6) and 
61.9% (CYP2C19). This means that more than half of all psychiatric patients have a 
non-normal predicted CYP2D6 and/or CYP2C19 metabolizer phenotype. Since >75% 
of the psychopharmacological drugs are metabolized by one or both of these 
enzymes (29,125), the results of our meta-analysis emphasize the importance of 
integrating pharmacogenetic information into clinical practice, especially when 
treating patients who have had adverse drug events or shown treatment resistance. 
We included a total of 318 studies in our meta-analysis of CYP2D6 and CYP2C19 
genotypes in healthy populations of which genotype requirements were fulfilled by 
118 studies (37%). This is an important requirement, because having too few CYP2D6 
or CYP2C19 alleles in a study may not accurately determine predicted phenotype 
from genotype data.  
 
Diversity within major ethnicities 
Although grouping populations can simplify reporting of pharmacogenetic alleles, 
we grouped ethnicities within geographical regions to enable comparisons with 
other published meta-analyses (126,127). The prevalences of our CYP2D6 predicted 
phenotypes were in general agreement with those reported by Gaedigk et al(11). 
However, our data predicted a higher percentage of UMs for Africans (i.e. 5.5%, 
n=562 versus 3.8%, n=430). This difference may be explained by the fact that we 
weighted the number of genotyped subjects when calculating the mean allele 
frequencies for our meta-analysis. In Gaedigk et al’s report, studies were not 
weighted by sample size, so small studies might have had a bigger influence on the 
mean. We also included two studies in Africans that were not included by Gaedigk 
et al due to their small sample size and thus not meeting their requirements of at 
least 50 study subjects; they both reported higher frequencies of UMs (104,128). In 
contrast, in the South Central Asian population the percentage of UMs found by 
Gaedigk et al was higher than those reported here, 2.8% (n=370) vs. 2.1% (n=434), 
due to the inclusion of two studies in South East Asians in this meta-analysis, which 
found no ultrarapid metabolizers (128,129) 
In contrast with Fricke-Galindo et al (82) and the CPIC’s CYP2C19 allele frequency 
table (https://www.pharmgkb.org/page/cyp2c19RefMaterials), we found a much 
higher prevalence of 25.0% for CYP2C19 UMs in Oceania (vs. 0% and 1.5%). This is 
because we only included studies investigating the CYP2C19*17 increased function 
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allele, which leads to rapid and ultrarapid metabolizer predicted phenotypes. Studies 
that do not investigate this allele yield underestimates of the prevalence of UMs.  
 
Clinical practice 
Some issues need to be addressed in translating genotype data to information useful 
for clinical practice. Although prevalences of non-NM are high, there is no conclusive 
evidence whether CYP genotyping is beneficial for clinical outcomes in psychiatric 
practice. There are a few prospective studies analyzing the clinical utility of CYP 
genotyping and they report contradictory outcomes in diverse populations (7,87,88). 
So far, it is still unclear which patient groups might benefit from genotyping and see 
better treatment outcomes. One reason for the uncertainty is the possibility of the 
transformation of genotypic EMs into phenotypic PMs by multiple causes, for 
example, due to smoking, CYP2D6 and CYP2C19 inhibiting medication (e.g. 
bupropion and esomeprazole), CYP2D6 and CYP2C19 inducing medication (e.g. 
oritavancin and carbamazepine), and inflammation or co-morbidities (16,130). This 
phenomenon is called phenoconversion: it has been described in diverse populations 
(17,18,131). If this is happening on a large scale, it means genotypic outcomes could 
be unreliable for use in clinical practice. It may already influence outcomes of studies 
on the effectivity of CYP genotyping in clinical practice (88). Another issue may arise 
with genotyping patients who have been on treatment for several years, because 
their brain has adapted to the changed levels of neurotransmitters and the side-
effects are no longer reversible (132,133). 
Lastly, the category of the intermediate metabolizer has been the subject of 
debate(134). In this meta-analysis we categorized the IM as defined by the CPIC (33). 
Because IMs only show minor differences in metabolism from EMs (135), one could 
categorize them in the NM group. However, other studies have indicated that IMs 
show lower oral drug clearance, higher blood serum levels, and have higher chances 
of side-effects than EMs (136–138). For this reason, we consider the IM status is 
clinically relevant for psychiatric patients and guidelines for some medications are 
now advising dose adjustments for this predicted phenotype (44,139). Estimations of 
the worldwide prevalence of only PM+UM were 7.75% (CYP2D6) and 32.94% 
(CYP2C19) (Supplemental Figures 1+2). 
 
Strengths and limitations 
We included studies with a small number of participants (n≥20), as well as controls 
from case-control studies, which increased the number of studies we could include. 




prevent confounding our data (i.e. disease-associations with specific allele 
frequencies (140–146)). On the other hand, some large studies had to be excluded 
due to their inclusion of non-healthy individuals which might have biased the 
outcomes of some countries (147). 
Another strength is that we used region-specific inclusion criteria to maximize the 
accuracy of the phenotype predictions (11,82,86). This helped to avoid applying 
criteria based on studies in Western countries to other regions of the world. This led 
to the exclusion of studies reporting on too few allelic variants, and of studies 
focusing on the determination of only poor or ultrarapid metabolizers in a 
population (81,148,149).  
Studies reporting allele frequencies of merely CYP2C19*2 and *3 or studies 
investigating CYP2D6 allele duplications, but with no minimum set of variants, are 
certainly of scientific importance, but not of practical importance for clinicians 
because no complete risk inventory of the metabolizer phenotype could be 
determined. Because we excluded studies not investigating CYP2C19*17, we had 
only one report describing Oceanians (n=24) (150), which did not identify any PMs.  
A limitation is that we were depended on the sensitivity of the tests of the individual 
studies. For example, because of overlap in SNPs in the CYP2D6*10 and *36 and in 
the CYP2D6*17 and *40 allele, a slight over- or underestimation of some predicted 
phenotypes might have been reported in some studies (151).  
The inclusion of studies with a small number of participants (20-50) could have led 
to an over- or underestimation of predicted phenotypes in some populations, but 
the influence on the mean prevalence was minimized by weighting the number of 
genotyped subjects. We may still have made over- or underestimates where there 
are few studies for a certain region/country along with a relatively small number of 
studied subjects. Because few studies reporting specific minority ethnicities met our 
inclusion criteria, we did not want to exclude potentially valuable information from 
our meta-analysis by setting too-stringent participant number requirements.  
Although we only included studies on homogenous ethnic groups in this meta-
analysis, we are aware of the limitations of grouping ethnicities based on self-
reported ethnicity. Although ancestry based on genetic information is more objective 
than self-reported ethnicity, much of the research into CYP genotypes has been 
based on self-reported ethnicity, while for a few minority populations, some genetic 
data were systematically analyzed. In a study of 103,006 participants with 23 
ethnicities, a very high correspondence was found between self-reported ethnicity 
and genetic ancestry (152). Only African-Americans and Latino-Americans 
demonstrated a higher degree of ancestral admixture than self-reported. 
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Second, although studies of genetic ancestry show there is a strong linkage between 
belonging to an ethnic group and coming from a certain geographical region, 
ethnicity is not always the same as geographical region (101). Ethnic groups migrate 
and although some ethnicities show almost no admixture with the local ethnicity 
even many years after migration, other ethnicities do show a mixture of multiple 
ancestors. 
Especially in countries in the Americas, North America and Canada ethnic 
backgrounds can be diverse and individual ethnicity is increasingly blurred by 
admixture, making self-reported ethnic background or geographical location less 
predictive for a correct estimation on a non-normal metabolizer predicted 
phenotype (130). The probability estimates per country (Figures 2-5) are means of 
the probability estimates of these different ethnicities and must therefore be 
interpreted with caution. 
The total means are mean probability estimates of all the included populations and 
represent a worldwide mean probability estimate. Because countries were not 
weighted by number of inhabitants, small countries with large study populations 
have a relatively large influence on the estimated mean. In addition, some 
geographical regions were significantly under-investigated (Africa and the Middle 
East) and their predicted phenotype distributions are not adequately represented in 
the total estimated means.  
 
Conclusions 
In this comprehensive meta-analysis of worldwide CYP2D6 and CYP2C19 genotype 
variation, (>336,000 subjects, 318 reports), we found that the mean total probability 
estimates for a non-normal metabolizer predicted phenotype are 36.4% for CYP2D6 
and 61.9% for CYP2C19. The estimates reveal a large geographical variation (3-61% 
and 32-80%, respectively). Our results suggest that more than half of the world 
population has a non-normal CYP2D6 and/or CYP2C19 metabolizer predicted 
phenotype. Based on the documented probability estimates, pre-emptive 
pharmacogenetic testing is encouraged for every patient who will undergo therapy 
with a drug(s) that is metabolized by CYP2D6 and/or CYP2C19 pathways, and should 
be considered in case of treatment resistance or serious side effects.   
Secondly, many of the studies were not relevant for clinical practice, because they 
only investigated a minimum number of allelic variants and thus any phenotype 
prediction is unlikely to be accurate. Especially when estimating the prevalence of 
the CYP2C19 UM predicted phenotype, studies in all regions except for East Asia, 
should genotype on *17 to come to a reliable phenotype prediction. We therefore 




alleles – depending on the geographical region – must be assessed to be able to 
predict phenotypes as accurately as possible (153). 
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Aim: This study was aimed to assess the prevalence of CYP2D6 and CYP2C19 
polymorphisms in psychiatric patients and in volunteers from Dutch Caribbean 
origin.  
Methods: In total, 435 individuals were genotyped for CYP2D6 and CYP2C19. Of 
these, 269 were psychiatric patients living in Curaçao and 166 were volunteers from 
the Dutch Caribbean population.  
Results: No differences in prevalence of alleles were found.  
Conclusion: Although prevalence of alleles appeared to be very different from African 
and Caucasian populations, the distribution into predicted phenotypes shows an 
equal distribution as in Caucasians. 
 
ClinicalTrials.gov: Cost-effectiveness of CYP2D6 and CYP2C19 Genotyping in 
Psychiatric Patients in Curaçao; Identifier: NCT02713672;  
URL: https://clinicaltrials.gov/ct2/show/NCT02713672?term=CYP2D6&rank=5 
 




The cytochrome P450 (CYP) is the most important pathway for the metabolization of 
lipophilic drugs into more hydrophilic compounds, which can be excreted by the 
kidneys. Humans have 57 genes that encode for over 30 related isoenzymes with 
different substrate specificities (12). The isoenzymes CYP2D6 and CYP2C19 are highly 
genetically polymorphic and are specifically related to the metabolism of psychiatric 
drugs (27–31). Depending on the number of functional alleles, individuals are 
classified as Poor Metabolizer (PM), Intermediate Metabolizer (IM), Extensive 
Metabolizer (EM) or Ultrarapid Metabolizer (UM) (6). Because of the lower 
metabolization ratio, PMs and IMs have higher blood concentrations at 
recommended dosages of the medication metabolized by the CYP enzymes; this 
makes them more vulnerable to the dose-dependent adverse effects of 
psychotropics in normal dosages (22,24,154–156). Simultaneously, exceeding D2 
receptor occupancy leads to suboptimal subjective experiences in patients with 
schizophrenia, leading to less effective treatment (157).  
Studies in psychiatric patients found a significant relationship between the CYP2D6 
profile and extrapyramidal symptoms (21,138,158–161).  
In addition to the role of CYP2D6 genetic polymorphisms in drug metabolism, 
CYP2D6 is suggested to play a role in the risk for developing a mental disorder. In 
biochemical studies CYP2D6 was suggested to be functionally similar to the 
dopamine transporter and to have an endogenous neuroactive substrate or product 
(162); this has been proposed as an explanation for the relationship found between 
personality and activity of CYP2D6 (163). Also a lower frequency of poor metabolizers 
was found among inpatients with schizophrenia (67), although earlier studies did not 
find these differences (83,106,164–168). 
The prevalence of CYP polymorphisms varies considerably across ethnic groups, 
which leads to great interindividual drugs responses across different ethnicities (57). 
In Caucasian populations, for example, the prevalence of CYP2D6 UM ranges from 
1-10% (13,169,170) as compared to 20-29% in specific African populations (81). 
Allelic variants * 29 and *17 are considered unique to Sub-Saharan African 
populations (171).  
Curaçao is one of the western Leeward Antilles in the Caribbean. Together with Aruba 
and Bonaire it forms the ‘ABC’ islands. Until 2010, these islands (together with St 
Maarten, Saba and St. Eustatius) formed the Netherlands Antilles. The population 
originates mainly from Western Africa but has admixed with European immigrants 
and Native South Americans. Recently it has been shown that the complex 
interactions between the populations in the Caribbean are reflected in a unique 
composition of genes. Also was shown, that the extensive population stratification 




In a recently published systematic review Céspedes-Garro et al. argue that research 
activity on pharmacogenetics in Caribbean populations is limited and the prevalence 
of CYP2D6 and CYP2C19 in the former Netherlands Antilles remains unknown (59). 
Therefore, we investigated the prevalence of CYP2D6 and CYP2C19 in a population 
from the Dutch Caribbean. To test the hypothesis that CYP2D6 may play a role in the 
risk for severe psychiatric disorders, we compared the prevalence of CYP2D6 
between psychiatric patients on psychotropic medication and individuals from the 




Setting and study population 
This study was performed on the Caribbean island of Curaçao and also in the 
Netherlands. The population of Curaçao (approx. 150,000 inhabitants) is mainly of 
African descent. Participants were recruited from the Klinika Capriles (the only 
psychiatric hospital on the island), the psychiatric ward of the local prison (FOBA), 
and the psychiatric outpatient department on the island (Psychiaters Maatschap 
Antillen). All three institutions provide specialist mental health care and diagnoses 
are assigned by psychiatrists. 
The majority of patients in these institutions are suffering from severe mental illness. 
Earlier studies in this population showed that 77.3% of the patients is diagnosed with 
schizophrenia (8). The objectives of the study were explained to all patients in their 
native language and they were asked to participate before enrollment. All 
participants provided written informed consent after explanation of the study, and 
received a gift token of about 10 euro if they participated. 
The study protocol was approved by the Institutional Review Board of Maastricht 
University (the Netherlands) and ethical approval to collect samples was received 
according to local policies by the patient board of the Klinika Capriles. The 
procedures were in accordance with the ethical standards of the Helsinki Declaration 
of 1975 (as revised in 1983).  
Inclusion criteria were: 1) Antillean ethnicity, defined in line with the concepts used 
by Statistics Netherlands (CBS) as birth on the former Netherlands Antilles and birth 
of at least one parent on the former Netherlands Antilles, 2) age 18 years or older, 3) 
use of an antipsychotic or antidepressant drug, and 4) written informed consent. 
Clinical information about the use of cardiovascular, intramuscular and other 
medication was also collected. 
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To compare our findings with an Antillean population from the general population, 
we asked Dutch Caribbean visitors at several large Antillean gatherings in the 
Netherlands for permission to examine their CYP2D6 and CYP2C19 profile. Curaçao 
is a former Dutch colony and since decennia inhabitants from Curaçao are migrating 
to the Netherlands. Currently there are as many Antilleans living in the Netherlands 
as in Curaçao (62). This sample was constructed between June 2012 and March 2013. 
The inclusion criteria were in line with the Curaçao part of the study, with the 
exception that no antipsychotic or antidepressant drugs were used. Participants were 
asked about medication use and their health condition. Participants received a gift 
token of 25 euro.  
We compared the prevalence of the Dutch Caribbean population with populations 
from Caucasian and African origin. To enable a valid comparison between the 
prevalence of predicted phenotypes, our results were compared with studies having 
a similar methodology. Although we searched for studies reporting predicted 
phenotypes and determining (minimally) the same polymorphisms as in our study, 
this appeared to be more difficult than expected. Therefore, we decided that Greece 
and Portugal could represent the Caucasian population, and that Uganda could 
represent Sub-Saharan Africa (172–174).  
To evaluate clinical relevancy of genotyping in psychiatric practice, we evaluated if 
there were any differences in clinical admission, prison admission, use of 
intramuscular emergency medication, clozapine, biperidene and cardiovascular 
medication between the different phenotype groups. 
To evaluate possible clinical consequences, patients were selected for dose 
adjustment based on their CYP2D6 and CYP2C19 genotype. The influence of dose 
adjustment on psychiatric well-being and side effects was assessed. The results of 
this study have been reported in a separate paper (88). 
 
CYP2D6 and CYP2C19 genotyping 
Saliva from each participant was collected with a 2-ml cannula OG-500 DNA Genotek. 
The saliva was kept at room temperature and sent to the Erasmus Medical Center 
(Rotterdam, the Netherlands) for genotyping. Samples were analyzed using the 
INFINITI DNA chip (Autogenomics, Carlsbad, CA) for detection of CYP2D6 
polymorphisms *1, *2 (2850C>T and 1584C>G), *3 (2549delA), *4 (1846G>A), *5 
(deletion), *6 (1707delT), *7 (2935A>C), *8 (1758G>T), *9 (2615_2617delAAG), *10 
(100C>T), *17 (1023C>T), *29 (1659G>A), *41 (2988G>A) and gene duplication. For 
samples that did not yield a valid result in the INFINITI DNA chip, Taqman (ABI Prism 
9700 HT Sequence detection system) and PCR-RFL was used. CYP2C19 




determined using Taqman and PCR-RFL. The different variants of CYP2D6 and 
CYP2C19 at the DNA and protein level are described at 
http://www.cypalleles.ki.se.htm.  
Genotypes were grouped according to the Dutch Pharmacogenetic Guideline of the 
Royal Dutch Association for the Advancement of Pharmacy (consensus meeting). A 
normal function allele is scored 1, a reduced function allele is scored 0.5 and a non-
functional allele scored 0 (http://www.cypalleles.ki.se/CYP2D6.htm). Homozygous 
carriers of deficient alleles are classified as PMs (0). Carriers with one functional allele 
and one non-functional allele and homozygous carriers of reduced function alleles 
are classified as IMs (0.5-1). Homozygous carriers of normal function alleles and 
carriers of one reduced function and one normal function allele are classified as EMs 
(1.5-2). Carriers of one or more increased function alleles and carriers of a duplication 
or multiplication of a functional allele are classified as UMs (>2) (175,176). CYP2D6 
polymorphisms *1 and *2 were classified as 1, *3 - *8 as 0 and *9, *10, *17, *29 and 
*41 as 0.5. Carriers of two *1 polymorphisms were classified as EMs. Carriers of one 
CYP2C19 *2 polymorphism were classified as IMs and carriers of one and two *17 




Analyses were performed with IBM SPSS statistics (version 22) and GENEPOP 
(177,178). The significance limit used in all analyses was ɑ = 0.05. A χ2 test was used 
to make comparisons between the groups in prevalence and clinical parameters. A 
Fisher exact test was used if expected cell count was lower than 5. We used a 
Bonferroni correction if multiple tests were performed. The distributions of the 









From the total inpatient population of 196 patients of the Klinika Capriles (the only 
psychiatric hospital in Curaçao), 180 (91.8%) patients met the inclusion criteria and 
participated in this study. Furthermore, all 10 patients of the forensic psychiatric ward 
in the local prison, and 79 outpatients who met the inclusion criteria were included, 
yielding a total of 269 study participants.  
Four saliva samples (collected from 3 inpatients at Klinika Capriles and 1 outpatient) 
were lost during transport to the Netherlands. In 13 samples, CYP2D6 was repeated 
using Taqman and PCL-RFL. Genotyping succeeded for CYP2D6 in 231 (85.9%) 
participants and for CYP2C19 in 187 (69.5%) participants. Failure of genotyping was 
due to the low quality DNA obtained from the buccal swabs. Patients in Curaçao 
were instructed to deliver saliva by the local nurses, which could explain less accurate 
collection of saliva. The samples, which could not be used for genotyping, had a lack 
of saliva or were contaminated with food residues. There were no significant 
differences between those with a successful CYP2D6 or CYP2C19 genotyping and 
those without regarding gender, place of treatment, use of antipsychotics, 
antidepressants and other medication.  
No differences in clinical admission, prison admission, use of intramuscular 
emergency medication, clozapine, biperidene and cardiovascular medication were 
found between the CYP2D6 and CYP2C19 phenotype groups. Age was significantly 
different between the CYP2C19 phenotype groups (ANOVA p=0.008). Table 1 
presents the characteristics of the different phenotype groups. 
Out of the 269 patients, 42.0% used antipsychotic or antidepressive medication 
metabolized by CYP2D6 and 1.5% used antidepressive medication metabolized by 









In the Netherlands, 166 Dutch Caribbean participants were genotyped. These 
participants were selected from the general population, 68 (41.0%) were using 
medication (mostly cardiovascular drugs). The CYP2D6 could not be established in 
three persons and the CYP2C19 genotype remained unknown in 21 persons.  
 
Genotypes 
In total, 435 Dutch Caribbean persons from two samples were genotyped. The 
genotyping was in both groups in concordance with Hardy-Weinberg equilibrium 
(psychiatric patients in Curaçao; CYP2D6 p=0.07, CYP2C19 p=0.38; Dutch Caribbeans 
in the Netherlands; CYP2D6 p=0.28, CYP2C19 p=0.92). 
There were no differences between the Dutch Caribbean psychiatric group from 
Curaçao and the Dutch Caribbean non-psychiatric group living in the Netherlands in 
gender. Mean age was higher in the psychiatric patients group 49.5 (13.0) versus 44.6 
(15.9) years (p=0.0005). 
No significant differences in CYP2D6 and CYP2C19 allelic frequency between the two 
groups were found. The frequencies of the CYP2D6 predicted phenotypes showed 
an equal distribution between the two groups. In the Dutch Caribbean non-
psychiatric group living in the Netherlands there were significantly more CYP2C19 
CYP2D6 and CYP2C19 genotyping in the former Dutch Antilles 
57 
 
poor metabolizers than in the Dutch Caribbean psychiatric group from Curaçao 
(Fisher exact p=0.02). 
Table 2 and 3 present these results, compared with other ethnic populations. 
CYP2D6*17 was the most prevalent mutant allele (16.2%). The most frequent non-

















Comparison with other ethnicities 
To our knowledge, this is the first study to investigate the prevalence of the 
polymorphisms of CYP2D6 and CYP2C19 in this specific Caribbean population. The 
former Netherlands Antilles have a long history of different ancestors and the current 
population is very heterogeneous. Arawaks were the native inhabitants before 
Europeans colonized the island and brought slaves from West Africa to the island. 
Immigrants from Latin America, other Caribbean islands and East Asia, came to the 
islands after slavery was abolished and admixed with the local inhabitants (179). 
Moreno-Estrada et al. found that this admixture can result in geographically 
restricted medically relevant genetic variations (60). Therefore, it is important to 
investigate the impact of this admixture of ancestors on allele composition. 
One difficulty in comparing our prevalence rates with others is the ongoing detection 
of unknown mutations, which has resulted in overestimation of the prevalence of 
wild type genotype, namely CYP2D6*1 and CYP2C19*1. To allow to predict the 
correct phenotype in patients of all nationalities, we tested for the most common 
gene mutations worldwide; CYP2D6 *1, *2, *3, *4, *5, *6, *7, *8, *9, *10, *17, *29, *41 
and CYP2C19 *1, *2, *17(180). (180). CYP2C19*17 is a relatively novel variant causing 
ultrarapid metabolism and is responsible for the overestimation of extensive 
metabolizers in many studies (174). In the present study we found a high prevalence 
of CYP2C19*17, i.e. 20.0%. 
Furthermore, noteworthy is the relatively high prevalence of CYP2D6*4 of 11.0%. In 
Sub-Saharan African populations non-functional alleles as *4 occur at a relatively low 
frequency with a median rate of 3.36%. Only in the Ghanaian population a higher 
rate of 7% is reported (57). This is interesting because the ancestors of the inhabitants 
of Curaçao are suggested to originate mainly from West Africa, which could imply a 
Ghanaian heritage (179). Another explanation could be heritage from the Dutch 
colonists because, in Caucasians, the polymorphism is relatively prevalent (18.5%) 
(176). In the present study, the frequency of CYP2D6 alleles is similar to that in an 
Afro-Caribbean population from Trinidad and Tobago – who are also suggested to 
originate from (West) Africa – except for the prevalence of *4, which is 1.94% in 
Trinidad and Tobago [45].  
Reduced function allele CYP2D6 *17 occurs at a prevalence of 16.2% in Curaçao 
compared to 20% in Sub-Saharan Africa and a very low prevalence of 0.32% in 
Caucasians (176). CYP2D6*10, which can be as high as 74% in Asian populations, is 
not as prevalent in the Curaçao population (i.e. 3.6%) (114). This suggests that the 
inhabitants of the former Netherlands Antilles are mainly an admixture of Caucasians 
and Sub-Saharan Africans, with much less admixture between descendants of the 




The prevalence of the polymorphisms CYP2C19 is less widely distributed among the 
different ethnicities. With a prevalence of normal function CYP2C19 *1 of 64.6% in 
inhabitants of the Dutch Caribbean, this almost equals the prevalence of 68% in 
Africans and 63% in Caucasians. Reduced function allele *2 and *17 are prevalent in 
amounts similar to those in Africans and Caucasians (181).  
Comparison of the predicted phenotypes with other ethnicities provides interesting 
insights: even though CYP2D6 genotypes differ greatly between the investigated 
population and Caucasians, the prevalence of predicted phenotypes is very similar.  
 
Comparison between psychiatric patients and general population 
We found no difference between the allelic frequencies in the cohort of psychiatric 
patients versus a comparable group of non-psychiatric Dutch Caribbean volunteers. 
Several clinical studies found lower frequencies of CYP2D6 poor metabolizers in 
admitted patients with schizophrenia (22,67), whereas other did not find this 
difference (83,106,164–168). A possible explanation for this is that CYP2D6 plays a 
role in the biotransformation of several neurotransmitters. CYP2D6 may be involved 
in the formation of dopamine from tyramine and therefore contributes to 
vulnerability for schizophrenia and may have influence over personality (140,162). 
There is, however, no evidence that these biochemical processes occur in psychiatric 
patients. 
In the present study, almost 30% of the psychiatric population is outpatient. 
Moreover, because the control group is from the same ethnic background, our 
findings are not influenced by ethnic differences. The studies which found a 
difference investigated a selected inpatient population compared with healthy 
outpatient volunteers (22,67). In patients with depression it was shown that length 
of hospitalization is correlated with CYP2D6 functional status (5). The selection of 
inpatients might have confounded the results. In our population there were no 
differences in predicted phenotype frequencies between in and outpatients. 
We found no CYP2C19 poor metabolizers in psychiatric patients in contrast to 4.1% 
in the healthy volunteers. The absence of CYP2C19 poor metabolizers is also 
reported in Panamanian Indian and Mexican populations (182,183). The Indian in 
heritage could be an explanation for the low prevalence among our subjects. There 
is no convincing relationship between CYP2C19 and psychiatric symptoms(46). 
Although in a Swedish population poor metabolizers had significantly lower levels of 
depressive symptoms than extensive metabolizers, with a stronger relationship in the 
younger age groups (184). This might also have influenced the mean age in our 
psychiatric population. 




A limitation of this study is the selection of a heterogeneous group of psychiatric 
patients. We have not investigated the prevalence of CYP2D6 or CYP2C19 in specific 
psychiatric disorders. Since we wanted to investigate the prevalence in a group for 
which results could have clinical implications, we investigated prevalence in all 
patients with a psychiatric disorder and use of psychotropic medication.  
Another important limitation of this study is the relatively large percentage of 
missing saliva samples as compared to studies investigating DNA by blood sampling. 
However, because genotyping from saliva is non-invasive, we were able to genotype 
a large cohort of individuals. Unfortunately, genotyping of CYP2C19 failed in of 24% 
of the samples. Nevertheless, because no differences were found between the 
successfully genotyped group and the group with missing genotype and results are 
within expected frequencies of the HWE, missing data are not expected to have 
influenced our results.  
 A third limitation is the relatively small sample size of the study because of the small 
percentages we found for some CYP2D6 polymorphisms. For this reason, these 
findings cannot be generalized to the broader community based on this study alone. 
 
Conclusion 
In summary, this study reveals a unique composition of alleles in the population of 
the former Netherlands Antilles. The complex admixture of ancestors was shown in 
the unique composition of alleles of CYP2D6. Although we found a completely 
different allele composition than found in Caucasians, the translation into predicted 
phenotypes shows an almost similar distribution between these groups.  
No differences in allelic frequency were found between psychiatric patients and non-
psychiatric volunteers. Although a higher frequency of CYP2C19 poor metabolizers 
was observed in the non-psychiatric volunteer group.  
These findings imply that, in clinical practice the same attention should be paid to 








• We found a unique prevalence of specific CYP2D6 and CYP2C19 alleles in 
the Dutch Caribbean population. 
• The most frequent non-functioning CYP2D6 allele in the Dutch Caribbean 
population is *4.  
• The most frequent variant CYP2C19 allele causing ultrarapid metabolism in 
the Dutch Caribbean population is *17.  
• No significant difference was found in the alleles in psychiatric and non-
psychiatric Dutch Caribbean subjects. 
• No significant difference was found for variability of CYP2D6 activity 
between the Dutch Caribbean population and Caucasian populations. 
• There were significantly more CYP2C19 poor metabolizers in the Caribbean 
non-psychiatric volunteer group. 
• The same attention should be paid to altered drug clearance in inhabitants 
from the Dutch Caribbean, as is paid to Caucasians. 
 
• Our findings provide further evidence for geographic-specific admixture and 
uniqueness and heterogeneity of populations of Caribbean descent. 
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Background The CYP2D6 enzyme is involved in the metabolism of numerous 
psychopharmacological drugs. Guidelines recommend how to adjust the dose of 
medication based on the CYP2D6 genotype.  
Aims To evaluate the effect of dose adjustment to the CYP2D6 genotype and 
phenotype, in patients with severe mental illness (SMI) already receiving 
psychopharmacological treatment. 
Method A total of 269 psychiatric patients (on the island Curaçao) receiving 
antipsychotic treatment were genotyped for CYP2D6. Of these, 45 patients were 
included for dose adjustment according to the clinical guideline of the Royal Dutch 
Association for the Advancement of Pharmacy, i.e. 17 CYP2D6 poor metabolizers, 26 
intermediate metabolizers, and 2 ultrarapid metabolizers. These 45 patients were 
matched for age, gender and type of medication with a control group of 41 patients 
who were CYP2D6 extensive metabolizers (i.e. with a normal CYP2D6 function). At 
baseline and at 4 months after dose adjustment, subjective experience, 
psychopathology, extrapyramidal side-effects, quality of life, global functioning were 
assessed in these two groups.  
Results At baseline, there were no differences between the groups regarding the 
prescribed dosage of antipsychotics, the number of side-effects, psychiatric 
symptoms, global functioning or quality of life. After dose adjustment, no significant 
improvement in these parameters was reported.  
Conclusion In psychiatric patients with SMI already receiving antipsychotic treatment, 
dose adjustment to the CYP2D6 genotype or phenotype according to the guidelines 
showed no beneficial effect. This suggest that dose adjustment guidelines are 
currently not applicable for patients already using antipsychotics.  
 
Keywords: CYP2D6, severe mental illness (SMI), guidelines, dose adjustment, 
genotyping, psychopharmacology, personalized medicine 
 




The cytochrome P450 isozymes, in particular CYP2D6, is responsible for the 
biotransformation of many psychopharmacological drugs(12,13). Substrates of 
CYP2D6 include first generation antipsychotics, selective serotonin receptor 
inhibitors and tricyclic antidepressants1. Based on genetic variation, patients can be 
divided into poor metabolizers (PM), intermediate metabolizers (IM), extensive 
metabolizers (EM) and ultrarapid metabolizers (UM). The recommended dosages of 
psychopharmacological medication that are metabolized by this enzyme are based 
on the metabolism of the most common genotype, i.e. the EM type (i.e. a normal 
CYP2D6 function). However, because the plasma level of a drug is related to the 
genotype, the same dosage will probably lead to a higher plasma level in PMs and 
IMs, as compared to EMs, and to a lower plasma level in UMs as compared to EMs. 
The plasma level is often related to the effectiveness of the drug and the risk of dose-
related side-effects (20–23,25). Also, when physicians prescribe a drug metabolized 
by CYP2D6 without taking into account the genotype, the hospital stay is longer (and 
the costs higher) in patients with a PM and UM profile(5).  
Clinical guidelines recommend dose adjustment according to the CYP2D6 genotype 
(44,85,185). However, the current guidelines do not differentiate between patients 
that start versus those that are already receiving psychopharmacological treatment. 
Patients with severe mental illness (SMI) are especially known to suffer from 
problems with adverse drug reactions, lack of medication effect, and new models of 
care are warranted (1,68–70,186). In a study in patients with SMI, more adverse drug 
events and higher costs were found in the extreme metabolizer groups(42). In a cost 
analysis study it was found that genotyping in patients with schizophrenia could lead 
to lower treatment costs (7). 
Genotyping in patients with SMI could potentially individualize treatment, reduce 
side-effects in slower metabolizers and increase treatment effects in rapid 
metabolizers. Until now, it remains unclear whether routine CYP2D6 genotyping is 
efficacious in patients with SMI already undergoing psychopharmacological 
treatment and evidence of clinical utility of CYP2D6 genotyping in patients being 
prescribed antipsychotics is lacking (6,27,187). We hypothesized that dose 
adjustment of antipsychotics to the CYP2D6 genotype and phenotype would be 
beneficial regarding side-effects, psychiatric symptoms, quality of life, and/or global 
functioning. The aim of the present study was to evaluate the effect of dose 
adjustment to the CYP2D6 genotype and phenotype, in patients with SMI already 
receiving psychopharmacological treatment. The dose adjustment group consisted 
of patients with a PM, IM or UM profile using antipsychotics metabolized by CYP2D6, 
whereas the control group consisted of patients with an EM geno-/ phenotype. The 
effect of dose adjustment of the antipsychotics on psychopathological symptoms, 






This study was performed on the Caribbean island, Curaçao: this is one of the western 
Leeward Antilles in the Caribbean with about 160,000 inhabitants2. Patients were 
recruited via the Klinika Capriles (the psychiatric hospital on the island), the 
psychiatric ward of the local prison (FOBA), and the psychiatric outpatient clinic 
(Psychiaters Maatschap Antillen).  
After being informed about the study procedures, all patients signed written 
informed consent. Inclusion criteria were: Antillean ethnicity (defined in line with the 
concepts used by the Central Office of Statistics in the Netherlands, as birth on the 
former Netherlands Antilles and birth of at least one parent on the former 
Netherlands Antilles); age ≥ 18 years; use of an antipsychotic or antidepressant drug; 
able and written informed consent. All participants in both groups received a token 
for 25 Netherlands Antillean Guilder (about US $13) if they completed the study. 
All DNA samples were genotyped July 2012 for CYP2D6 *1, *2, *3, *4, *5, *6, *7, *8, 
*9, *10, *17, *29, *41 in the Erasmus Medical Center (Rotterdam, the Netherlands) 
and gene duplication and grouped according to the predicted phenotype for 
CYP2D6 as described earlier (188).  
Diagnoses, demographic information and information on psychiatric and somatic 
medication was derived from the electronic patient file. The following psychiatric 
drugs were considered to have a major dependence on the CYP2D6 enzyme for their 
elimination: amitriptyline, aripiprazole, atomoxetine, clomipramine, imipramine, 
haloperidol, nortriptyline, paroxetine, pimozide, risperidone, venlafaxine and 
zuclopenthixol (44,85). 
Based on the CYP2D6 genotype or phenotype, patients were selected who were 
recommended a dose adjustment of their psychopharmacological medication 
according to the guideline of the Royal Dutch Association for the Advancement of 
Pharmacy (updated until July 2013). In this guideline, recommendations were 
developed for 53 drugs based on a systematic review of the literature. In CYP2D6 
PM, IM or UM patients, using medication metabolized by CYP2D6, it is advised to 
switch to a drug that is not metabolized by CYP2D6. An alternative is to adjust the 
dosage with dose reductions of respectively 25 to 50% of the original dose in IMs 
and PMs (44,85).  
To increase the power of the present study, patients who were PM or IM based on 
inhibiting medication were also included in the dose adjustment group (189). 
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Patients using strong CYP2D6 inhibitors (bupropion, cinacalcet, fluoxetine, 
paroxetine, quinidine) according to Flockhart’s interaction table, were classified as 
being PM (176,189).  
The selected patients were matched for age, gender and type of medication with a 
control group of patients who were CYP2D6 extensive metabolizers. 
All prescribed antipsychotics were calculated to a ‘defined daily dose’ (DDD) as 
reported by the World Health Organization (WHO) (190). This is a unit of 
measurement and defined as the assumed average maintenance dose per day for a 
drug used for its main indication in adults. The total equivalent of the DDD was 
calculated for every patient. The study protocol was approved by the Institutional 
Review Board of Maastricht University (the Netherlands) and ethical approval to 
collect DNA samples was received according to local policies by the institutional 
review board of the Klinika Capriles (Curaçao). 
The study was registered in an international trial registry at 
http://www.clinicaltrials.gov (NCT02713672). All procedures were in accordance with 
the ethical standards of the Declaration of Helsinki 1975 (as revised in 1983).  
 
Assessments 
Each patient underwent a thorough assessment of psychopathology, subjective 
experience, extrapyramidal symptoms, quality of life, global functioning and 
metabolic parameters at baseline (T0) (November-December 2014) and at four 
months after dose adjustment (T1) (April-June 2015). Information about drug and 
alcohol use was registered.  
The severity of the patient’s psychopathology was assessed with the Brief Psychiatric 
Rating Scale (BPRS) (191). Extrapyramidal symptoms were assessed with the St. Hans 
Rating Scale (SHRS) (192). Akathisia was measured with the Barnes Rating Scale for 
drug-induced akathisia (BARS) (193,194). Quality of life was assessed with the EQol 
5-D (EQ 5-D) (195). Global functioning was assessed with the WHO Disability 
Assessment Schedule 2.0 36-item proxy-administered version (WHODAS 2.0) and 
was administered with a personal caregiver (196,197); scores were recalculated to a 
standardized score. In all above-mentioned scales, higher scores indicate more 
severe symptoms. Subjective experience was measured with the Subjective Well-
Being Under Neuroleptics Scale (SWN-20) (198). Scores were recalculated, with 
higher scores indicating a higher level of well-being. For patients who were unable 
to read Dutch, the questions were translated into Papiamento (a local language). The 
investigator, a resident in psychiatry, was trained by professionals in scoring the 




measured the same number of days after administration of the depot at T0 and at 
T1. 
Secondary outcome measurements were metabolic parameters (blood pressure, 
body mass index (BMI), waist size, cholesterol, HDL, LDL, triglycerides, glucose, 
HbA1C and prolactin) and in 31 of the 60 patients receiving antipsychotics 
metabolized by CYP2D6 (dose adjustment group n=22, control group n=9), the 
plasma levels of antipsychotics were measured.  
 
Procedures 
After baseline measurements, another psychiatrist in training prescribed the dose 
adjustments. A standard procedure for dose adjustments was followed. Lowering the 
dose was done in steps according to a local protocol3(199). Tranquilizing medication 
with inhibitory activity was replaced by benzodiazepines. By removing the inhibiting 
medication, no further dose reduction was necessary in these patients. Complex 
cases were discussed with the research team during a regular meeting and individual 
dose adjustment plans were made.  
 
Statistical analysis 
Analyses were performed with IBM SPSS statistics (version 22). Differences between 
groups were tested with a Chi-square test for dichotomous variables and an 
independent t-test for continuous variables. ANOVA was used to compare means 
between the geno-/phenotypes. Non-parametric tests were used for variables not 
normally distributed (i.e. SHRS, BARS, EQ 5-D). Differences at T1 that were present at 
T0 were corrected for in an ANCOVA model. The relation between geno-/pheno and 
DDD was investigated with Kendall’s tau. All tests were two-tailed. The significance 
level was set at p <0.05. After Bonferroni correction, the significance level used was 
p < 0.005 (0.05/11).  
To analyse all aspects of deterioration, psychiatric well-being was evaluated on (one 
of) three scored items: i.e. deterioration was defined as a specific report by caregivers 
or a physician, or a >5-point increase on the BPRS, or on the WHODAS 2.0.  
A post-hoc power analysis showed that a 25% reduction of the psychiatric symptoms, 
or a 30% reduction of the symptoms measured by WHODAS 2.0, or a 75% reduction 
of the Parkinson symptoms, results in a power of 80% at a significance level of 0.05.  
 
  





The study population consisted of 269 long-term psychiatric patients, of which 94% 
was diagnosed with a psychotic disorder. Other diagnoses were major depressive 
disorder, bipolar disorder, substance abuse and intellectual disability. No regular 
drug or alcohol use was reported in any of the questionnaires. A quarter of the 
patients was outpatient. The majority (92%) was admitted in a long-term treatment 
facility or institutional housing at the start of genotyping and had a long treatment 
history. Every patient was genotyped 2.5 years before the start of the intervention, 
and for at least this period in treatment. Patients were stable on antipsychotic 
treatment for at least 2.5 years, three patients switched once from antipsychotic 
during this treatment period. 
Genotyping succeeded in 231 participants. Failure of genotyping was due to the low 
quality DNA obtained from the buccal swabs. Frequencies of PMs, IMs and UMs were 
similar to those found in an Antillean population without psychiatric disease(188); 
Caucasian populations(188); and in patients using antipsychotic medication not 
metabolized by CYP2D6. 
In total 111 out of 269 patients were using medication metabolized by CYP2D6. In 
total, 153 patients were prescribed two types of antipsychotics and 24 patients used 
antidepressant medication. Because the admitted patients received their medication 
from the nurses and two third of the patients were using depot medication we could 
account for medication adherence in 90% of the included patients. Figure 1 presents 
an overview of the patient selection and study procedure. The medication in the dose 







Figure 1.  Study procedure and inclusion of participants 
 
PM=poor metabolizer; IM=Intermediate Metabolizer, UM=Ultrarapid Metabolizer; EM=Extensive Metabolizer 
 
 
Out of 41 patients, 16 patients received a dose reduction. The mean dose reduction 
was 0.60 DDD, (1.4 DDD in PMs, 0.54 DDD in IMs) which equals a reduction from 5 
to 2 mg risperidone. Other patients stopped with their inhibiting medication or 
received alternative antipsychotic medication. Table 1 presents the patient 
characteristics and the outcome of measurements at T0 and T1. 
Four months after dose adjustment (T1), 81 (94%) patients were assessed for the 
follow-up measurements; one patient had died of cancer, two patients had 
withdrawn from psychiatric care, and two patients did not want to participate a 
second time. 






Baseline (T0)  
At baseline, no differences were found between the geno-/phenotype and the mean 
prescribed dose of antipsychotics as shown in Figure 2. In the dose adjustment group 
the mean DDD was 1.65 (SD 0.83) and in the control group it was 1.92 (SD 0.97) (Ns). 
PMs, IMs and UMs were prescribed the same amounts of psychopharmacological 
medication as the EMs.  
Second, we found no difference in dose-dependent adverse drug reactions between 
the normal and extreme metabolizers. Movement disorders were equally distributed 




Third, no differences were found between the normal and extreme metabolizers for 
psychiatric symptoms, subjective well-being and quality of life. There were no 
differences in psychiatric symptoms as measured by subscales of the BPRS. 
Because only 13 of the patients worked, the four items of the WHODAS 2.0 
concerning work were omitted. Patients with a PM genotype or phenotype scored 
higher on the WHODAS 2.0 than the IMs (PM 41.5, IM 26.6, EM 29.1, UM 34.0) 
(p=0.007); however, this difference was not significant after Bonferroni correction 
(p=0.005).  
Fourth, no significant differences were found between the dose adjustment and the 
control group in mean therapeutic drug plasma levels of antipsychotics metabolized 
by CYP2D6 (analysed with the Mann-Whitney U test). The mean therapeutic plasma 
levels at T0 of respectively the dose adjustment and the control group were for 
haloperidol 0.0015 mg/l (SD 0.0013) (n=4) and 0.0023 mg/l (SD 0.0006) (n=3) 
(p=0.35); risperidone 0.0173 mg/l (SD 0.0164) (n=9) and 0.0073 mg/l (SD 0.0081) 
(n=3) (p=0.34); zuclopenthixol 0.0143 mg/l (SD 0.0167) (n=9) and 0.0160 mg/l (SD 
0.0227) (n=2) (p=0.91). In the dose adjustment and control group there was a linear 
incremental relationship between dose and plasma level (data not shown).  
Separate analyses were performed with the exclusion of the 12 patients with a PM 
profile who were selected due to inhibiting medication (data not shown); however, 
this exclusion had no effect on the results. There were no differences in outcomes 
between males and females (data not shown). Table 2 shows the individual 
therapeutic plasma levels of antipsychotics (mg/l) metabolized by CYP2D6 of the 
nine patients in the dose adjustment group who participated in the measurements 
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Figure 2. Prescribed dose of antipsychotics in DDD per CYP2D6 geno/phenotype group at baseline 
 
Error bars +/- 1 SD, DDD=defined daily dose, PM=poor metabolizer, 









Effect of dose adjustment  
No significant effect of dose adjustment was found on psychiatric symptoms, quality 
of life, or global functioning. Of the 41 patients receiving dose adjustment, six 
returned to the original dose of the antipsychotics because of deterioration after 
dose adjustment. Deterioration of psychiatric symptoms resulted in two clinical 
admissions of outpatients of the dose adjustment group, whereas no admissions 
were reported in the control group; this difference was not significant. 
There was no significant difference in deterioration in psychiatric symptoms between 
the two groups. In the dose adjustment group, 16 patients (39%) showed a decline 
in one of three aspects (defining deterioration) compared with 14 patients (34%) in 
the control group. In patients who deteriorated, the mean prescribed dose of 
antipsychotics (in DDD) after dose adjustment was equivalent to the DDD in patients 
who remained stable (data not shown). Table 1 shows the mean changes in scores 
after dose adjustment (T1-T0). There were no differences in outcomes between males 
and females (data not shown). 
 
Effect of dose adjustment on side-effects and well-being  
Dose adjustment did not result in a significant improvement of parkinsonism, 
dyskinesia, dystonia or akathisia. There was a slight improvement (6%) in well-being 
as measured by the SWN-20. However, this is not considered a clinical relevant 
finding and is not significant after Bonferroni correction.  
 
Effect of dose adjustment on metabolic parameters 
Table 1 shows changes in metabolic parameters from baseline until after dose 
adjustment; no significant differences were found between the two groups. 
 
 




This study rejected the hypothesis that patients with SMI on antipsychotic treatment 
in a clinical setting benefit from dose adjustment based on the CYP2D6 genotype or 
phenotype. Importantly, at baseline, no differences were found in the severity of 
side-effects or global/psychiatric functioning between the dose adjustment group 
(with PM, IM and UM) and control group (with EM). There was no effect of dose 
adjustment on these parameters. 
We expected before we started the study that during years of treatment, clinicians 
would have optimized dosages to the geno-/phenotype based on side-effects or 
effectiveness of the drugs used. However, at baseline, the CYP2D6 PMs, IMs and UMs 
used the same amount of antipsychotics as the EMs. This finding motivated us to 
find out if dose adjustment could improve the clinical picture. A possible explanation 
for the absence of an effect, which could also explain the deterioration of some 
patients, is that long-term use of antipsychotics induces structural brain changes and 
adaptation of the brain to the changed dopamine levels occurs (132). It is suggested 
that antipsychotics play a role in the progressive reduction of brain size and 
enlargement of ventricular spaces in patients with schizophrenia, which is associated 
with involuntary movement disorders (200,201). Studies show that patients with 
long-term antipsychotic treatment have a threefold increase in loss of dopamine 
terminals in the substantia nigra (15% per decade vs. 5% in healthy controls) which 
is suggested to play a role in persistent parkinsonism and tardive dyskinesia (202). 
Additionally, it is reported that only 3% of patients discontinuing movement 
disorder-causing agents, resolved spontaneously from tardive syndromes and a 
reduction of the dosage of antipsychotics did not decrease the severity of 
parkinsonism (66,133). It could be that in this clinical population, a dose adjustment 
to CYP2D6 might have had an effect in an earlier disease stadium but after years of 
treatment has come too late.  
Another possible explanation for these findings is that in both our study groups, the 
baseline dosage of antipsychotics may have been so high (average DDD 1.65) that 
D2 receptor occupancy exceeded the optimal window for subjective well-being and 
to forestall extrapyramidal side-effects (40,41). This could explain why we found no 
differences in the prevalence of movement disorders and subjective well-being 
between the dose adjustment group and control group. However, no improvements 
in extrapyramidal and psychiatric symptoms were found in our patients using lower 
dosages of antipsychotics (DDD 1.0, after reduction DDD 0.5). 
Lastly, the role of the CYP2D6 genotype as a major factor in the metabolization of 
antipsychotics might be overestimated. The present study supports this hypothesis 




Another clinical study showed, that a proportion of healthy individuals with a PM 
genotype are phenotypically EMs as measured by CEIBA metabolization (203).  
In clinical practice, in patients with SMI, common factors as co-morbidities, 
inflammation, age, smoking and drug/alcohol use, could cause conversion of 
genotypic PMs into phenotypic EMs and the other way around (14–19). This 
undetected phenomenon, named phenoconversion, might explain the negative 
outcome effects in the present study.  
Although a small group of patients (n=14) remained stable with lower dosages of 
antipsychotics, no patients improved in clinical symptoms. This relatively minor 
saving in direct costs, did not weigh up to the costs of genotyping a large group of 
patients (n=269). 
 
Strengths and limitations 
This is the first study which prospectively investigated the clinical utility of dose 
adjustment to the CYP2D6 genotype or phenotype in patients on antipsychotic 
medication(6). The representativity was high as we were able to approach all 
psychiatric patients, with a homogenous African-Caribbean background in a 
restricted area, i.e. we included all three psychiatric institutes on the island of 
Curaçao. When including patients, no selection was made regarding the type of 
psychiatric care, medication, presence of side-effects or treatment response. This has 
resulted in a heterogeneous group of patients, representative for a general clinical 
population. It allowed us to analyse the effects of genotyping and dose adjustment 
in a clinical setting and has led to results with practical clinical value. We have no 
treatment history of the patients more than 2.5 years before the start of the dose 
adjustment but we know from clinical practice that patients with SMI make several 
switches in antipsychotics during the course of their illness and treatment. Earlier 
studies, in a larger population from this same clinic (66,204) show this is also true for 
this population. 
Although a large cohort of 269 psychiatric patients was genotyped, only a small 
number of patients (45) had an extreme geno-/phenotype and used medication 
metabolized by CYP2D6; therefore, a randomized controlled trial design was not 
possible. A control group was used to investigate differences between normal and 
extreme metabolizers before dose adjustment and to monitor possible effects from 
time. Furthermore, the design of the study, with a rater who was blinded to whether 
a patient was in the dose adjustment group or the control group, reduced possible 
expectation bias.  
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Ideally we would have analysed the effect of dose adjustment in patients using only 
one type of antipsychotic medication, due to the small numbers of extreme 
metabolizers this was not possible. Because all the investigated antipsychotics are 
metabolized by CYP2D6 as reported in the Flockhart table, it is very unlikely that this 
accounted for the absence of an effect. 
At last, the Food and Drugs Administration (FDA) provides a list of strong and weak 
inhibitors and, by inclusion of patients with a PM/IM phenotype based on interacting 
medication, greatly improved the prediction of the correct phenotype and has 
increased the power of the study(176,189). Post hoc power analysis showed that the 
number of included patients was high enough to demonstrate clinical relevant 
results. Moreover, not one out of 45 patients showed an evident improvement in side 
effects, psychiatric symptoms or functioning after dose adjustment and six patients 
returned to their original doses, due to deterioration of psychiatric symptoms. This 
supports the conclusion that adjustment of the dose based on the CYP2D6 geno-/ 
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Aims: This study explores how well the World Health Organization Disability 
Assessment Schedule (WHODAS 2.0) assesses problems with psychosocial 
functioning in patients with severe mental illness (SMI). Further, we assessed the 
relationships between psychosocial functioning and psychopathology, medication 
side effects, treatment setting, and quality of life. 
Methods: We performed an observational, cross-sectional study on the island of 
Curaçao to assess psychosocial functioning in 77 patients with SMI; they mainly had 
psychotic disorders. We interviewed their healthcare providers using the proxy 
version of the WHODAS 2.0. In addition, patients were examined for psychiatric 
symptoms, medication side effects (including drug-induced movement disorders), 
and quality of life. Associations were examined with Spearman’s rank correlation (ρ). 
Results: Difficulties in psychosocial functioning were reported by patients with SMI in 
the WHODAS 2.0 domains of Understanding and communicating (Mean (M)=34.5, 
standard deviation (SD)=18.6), Participation in society (M=25.5, SD=15.6), and 
Getting along with people (M=24.1, SD=16.1). Notably, outpatients had more 
problems participating in society than inpatients (M=33.6, SD=18.5 versus M=23.2, 
SD=14.1, p=0.03). A positive correlation was observed between drug-induced 
parkinsonism and the WHODAS 2.0 total score (ρ =0.30; p=0.02), as well as with 
various subscales, getting around and household activities. 
Conclusion: The proxy version of the WHODAS 2.0 is clinically useful for patients with 
severe mental illness. The highest scores on the WHODAS 2.0 were found in domains 
related to interactions with other people and to participation in society. Inpatient 
status appeared to aid participation in society; this might be due to living in the 
sheltered clinic environment and its associated daily activities. We further found that 
drug-induced parkinsonism was associated with a broad spectrum of psychosocial 
disabilities. 
  




The term ‘Severe Mental Illness’ (SMI) was introduced by the USA Substance Abuse 
and Mental Health Services Administration to differentiate between psychiatric 
patients with and without problems in daily functioning. Criteria for SMI include 
excessive disturbance and clinically significant distress or impairment in social, 
occupational or other important areas of functioning. Although, potentially, all DSM-
5 diagnoses can be involved,  
most of the patients who qualify as severely mentally ill have been diagnosed with 
schizophrenia, or another psychotic or major mood disorder. The prevalence of SMI 
in the USA is about 5% in adults (73). 
In the aim of treatment of patients with SMI, there is currently a shift in focus from 
care to recovery. Recovery is a process in which the most important goal is to regain 
a meaningful life in the community, including participation in valued activities and 
fulfillment of social roles (205–208). Participation in everyday activities, such as 
occupational or educational activities, coupled with adequate social functioning, are 
considered important indicators of recovery (206,209). Central to the monitoring of 
the recovery process is the measurement of patients’ psychosocial functioning. 
In DSM-5, the World Health Organization Disability Assessment Schedule (WHODAS 
2.0) was introduced as a better measure of psychosocial functioning in individuals 
with psychiatric disorders (210) than the earlier Global Assessment of Functioning 
(GAF). The WHODAS 2.0 was explicitly designed to exclude items on pathology to 
avoid confounding symptoms and functioning, which is a core problem with the GAF 
(211). 
Impaired psychosocial functioning in patients with SMI is multifactorial: adverse 
medication reactions (parkinsonism, obesity), and treatment setting (in- or 
outpatient) may influence functional recovery (1,186,212–214). For example, the 
medication side effect parkinsonism is associated with poor vocational performance 
(212), while some studies show positive results for community-based rehabilitation 
versus in-hospital treatment in patients with SMI (213–215). 
The WHODAS 2.0 offered valuable insight into patients’ experiences, had acceptable 
validity and psychometric properties, but it was challenging to use with patients with 
long-term psychotic disorders and several limitations were reported (74,76), e.g., 
caregivers generally reported worse functioning than patients themselves. A lack of 
insight (i.e., awareness of their illness and its consequences) in patients with SMI 
meant they registered fewer difficulties than expected in the questionnaire (74–76). 
Researchers also had to try hard to keep such patients focused on answering the 
questions, possibly because they had cognitive deficits (76). Using the proxy version 
of the WHODAS 2.0 could parry these limitations, since the interview is done with 
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the patient’s healthcare professional or a family member. Yet, to our knowledge, 
there are only a few publications about using it for patients with severe 
(neuro)psychiatric disorders (75,216,217). One study, in Ethiopia in patients with SMI, 
found that the proxy version had acceptable validity and psychometric properties, 
but higher mean values and better responsiveness to change than the patient 
interview version (75). 
Our study explored the use of the proxy version of the WHODAS 2.0 for assessing 
psychosocial functioning in a population with SMI. Further, we assessed the 
relationships between functioning and psychopathology, medication side effects, 




Our study was performed in the well-defined geographical area of Curaçao, an island 
in the Caribbean and part of the former Dutch Antilles. The study was also part of a 
clinical trial on CYP2D6 and CYP2C19 genotyping in patients with SMI (88). Our study 
population of 77 patients with SMI was part of the Curaçao Extrapyramidal 
Syndromes studies cohort (I-XIII) (8,66). AK, DV, PH and HH have worked as medical 
doctors on Curaçao.  
Our participants were inpatients recruited in November–December 2014 from the 
Klinika Capriles (the only psychiatric hospital on the island) and from the psychiatric 
ward of the prison, and outpatients recruited from the psychiatric outpatient clinic 
(Psychiaters Maatschap Antillen).  
Inclusion criteria for the study were: (1) Antillean ethnicity, defined according to the 
Dutch Central Bureau of Statistics as born on the former Netherlands Antilles, with 
at least one parent also born on the former Netherlands Antilles; (2) aged 18 years 
or older, and (3) meeting SMI criteria, defined as having a mental disorder causing 
functional impairment as shown by the need for intensive psychiatric care in or out 
of hospital. Exclusion criteria were: (1) refusal to give written informed consent, or (2) 
no family member or healthcare professional available and willing to participate in 
the study. 
We approached 86 patients, of whom 77 (90%; 30 females, 47 males) met our 
inclusion criteria. Eight patients were excluded because they had no healthcare 
professional or family member available for interview; one patient died before 
inclusion. After being informed about the study procedures, all patients signed an 
informed consent form. 
Proxy WHODAS 2.0 in severe mental illness 
85 
 
Of the 77 proxy questionnaires, two were completed by family members and 75 by 
healthcare professionals. The healthcare professionals were all nurses, with patient 
contact at least once a week. 
 
Measurements 
Each patient had a thorough assessment of psychopathology, subjective experience, 
extrapyramidal symptoms, quality of life, and global functioning. Demographic 
information was registered. In line with a previous study on SMI patients on Curaçao 
(8), in this study we used the diagnosis registered by the treating psychiatrist. The 
healthcare system on Curaçao meets Western standards and the majority of medical 
specialists are trained in the Netherlands. Information on psychiatric and somatic 
medication was derived from the electronic patient file. Until recently, Dutch was the 
only official language on Curaçao and we were able to communicate in Dutch with 
all healthcare professionals and family members. However, not all our study 
participants had completed secondary school education, and for those who did not 
understand Dutch (32 out of 77 patients), we communicated in the local language, 
Papiamentu, with the help of a bilingual hospital resident-in-psychiatry. To prevent 
outcome effects because of inter-rater variability, all measurements were done by 
the same investigator (AK). To prevent halo effects, the nurses were interviewed for 
the WHODAS with the interviewer blinded to the patient concerned. In this way we 
could ensure that there was no clinical prejudice in the way the interviewer scored 
the WHODAS items. 
 
Functioning 
Functioning was measured using the official Dutch translation of the proxy interview 
version of the WHODAS 2.0 (32 items), which was used with well-informed healthcare 
professionals or family members (218). Ideally we would also have used the patient 
version of the WHODAS 2.0 to provide information on the relationship between the 
two versions of the scale. This information would have helped to strengthen the 
rationale to use the proxy version of the scale. Previous studies have reported that 
patients with schizophrenia and schizoaffective disorders are poor raters of their level 
of functioning but good raters of other characteristics such as quality of life (219–
221). Higher levels of depressive symptoms are associated with underestimations in 
self-reports, while delusions and suspiciousness are associated with overestimation 
of functioning compared to interviewer judgments (222,223). In addition, co-authors 
DH and HH cooperated in the World Health Organization’s (WHO) development of 
the WHODAS 2.0 and concluded that the patient version was difficult to administer 
to patients with schizophrenia (224). Also, in a small pilot study, first author AK tested 
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this questionnaire. She found that concentration problems hampered the completion 
of the WHODAS 2.0 questionnaire, possibly due to its length (36 items) and the 
complex wording of some of the items. These concentration problems negatively 
affected the reliability of the answers and prompted our use of the informant version. 
Furthermore, almost none of the patients in the pilot and current study had 
completed secondary school, which may also explain the difficulties observed in the 
pilot patients when completing the WHODAS 2.0. Their low level of education may 
have resulted in problems in answering the complex questions. These observations 
supported our use of the informant version.  
The questionnaire measures patients’ functioning in six domains: (1) understanding 
and communicating (6 items), (2) getting around (5 items), (3) self-care (4 items), (4) 
getting along with people (5 items), (5) work and household activities (each 4 items), 
and (6) participation in society (8 items). Four items on work were not included in our 
study because almost none of the participants had a job – this is in line with the 
instructions in the Manual for WHO Disability Assessment Schedule WHODAS 2.0 
(225). 
Standardized summary scores range from 0-100, with higher scores indicating 
greater levels of disability in functioning (225). 
The patient interview version of WHODAS has a robust factor structure that is 
replicated across countries and populations, has high internal consistency 
(Cronbach’s α coefficient of 0.96 for its 36 items, good test-retest reliability (intraclass 
correlation coefficient of 0.98), good concurrent validity with other quality of life and 
handicap scales (correlation coefficients 0.45-0.65), and a reasonable sensitivity to 
change (effect sizes 0.44–1.38) (196,226). In the general population 90% has a total 
score of 35 or lower, indicating little or no disability in functioning (225). The proxy 
interview version shows good internal consistency (0.82-0.99) and good convergent 
validity in patients with severe mental disorders (75). It has a moderate sensitivity to 
change (0.14-0.57), which is nonetheless more sensitive than the patient version in 
this specific (SMI) population (0.17-0.35) (75).  
The interviewer, a resident-in-psychiatry (AK), was trained by experts (DH and HH) in 
scoring the WHODAS 2.0. 
 
Symptom severity and side effects 
The severity of patients’ psychopathology was assessed with the Brief Psychiatric 
Rating Scale (BPRS; 24 items). This rating scale has five subscales: Affect (anxiety, 
guilt, depression, somatic); Positive Symptoms (thought content, conceptual 
disorganization, hallucinatory behavior, grandiosity); Negative Symptoms (blunted 
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affect, emotional withdrawal, motor retardation); Resistance (hostility, 
uncooperativeness, suspiciousness); and Activation (excitement, tension, 
mannerisms–posturing) (191,227,228). Extrapyramidal side effects were assessed 
with the St. Hans Rating Scale (SHRS), a multidimensional rating scale for the 
evaluation of dyskinesia (18 items), parkinsonism (10 items), and dystonia (2 items) 
induced by antipsychotics. The dyskinesia is scored in two situations: in passive and 
active circumstances (192). Akathisia, a movement disorder and medication side 
effect, was measured using the Barnes Akathisia Rating Scale for drug-induced 
akathisia (BARS; 3 items) (193,194). 
For all the above scales, higher scores indicate more severe symptoms. AK, a 
resident-in-psychiatry, was the interviewer for all the scales; she was trained by 
experts in scoring the SHRS and BARS (PH and HH), and this included a training 
course with 10 Antillean patients with SMI on Curaçao. 
Patient experience of psychopharmacological medication side effects was measured 
with the Subjective Well-Being Under Neuroleptics Scale (SWN-20; 20 items). This is 
a self-rating scale that assesses subjective experience over the preceding seven days 
(198). For patients who were unable to read Dutch, the SWN-20 questions were 
translated into Papiamentu. Scores of negative statements were recoded to indicate 
that higher scores on all statements reflected higher levels of well-being. Drug-
induced weight gain was measured using Body Mass Index (BMI). 
 
Quality of life 
Quality of life was assessed with the EQol 5D (EQ-5D; 5 items), a widely-used scale 
that measures health status on five dimensions: (1) mobility, (2) self-care, (3) daily 
activities, (4) pain/discomfort, and (5) anxiety/depression (195,229). Higher scores 
indicate a lower quality of life. The EQ-5D shows some overlap with several WHODAS 
2.0 domains, including getting around, self-care, and work and household activities.  
 
Statistics 
All analyses were performed with IBM SPSS Statistics Version 25. Normality of the 
data distribution for all measurements was assessed by inspecting Q-Q plots. We 
conducted multiple regression analyses to identify how much age and gender 
contributed independently to the WHODAS 2.0 outcomes. The Mann-Whitney U test 
was used to compare outcomes between in- and outpatients. Correlations between 
the WHODAS 2.0 and the other measures were examined using Spearman’s rank 
correlation (ρ), with the significance level set at p <0.05. 




Patient characteristics  
Eighteen (23.4%) patients were outpatients and 59 (76.6%) were inpatients. The 
inpatients lived in housing on the clinic site and had been there for at least 2.5 years. 
Of those included in the study, 95% had a diagnosis of a psychotic disorder. Other 
diagnoses included depression, bipolar disorder, substance abuse, and intellectual 
disability. All patients were using antipsychotic medication (of these, 40 (52%) used 
biperidene and 45 (58%) were prescribed two types of antipsychotics). 
Antidepressant medication was prescribed for 7 (9%) of the patients, while 8 (10%) 
were using anti-epileptic medication and 33 (42%) were using cardiovascular 
medication.  
  
Distribution of total and domain scores of functioning  
The WHODAS 2.0 mean standardized domain and total scores are shown in Table 1. 
The mean total score of the 32-item WHODAS 2.0 scale was 31.2 (SD=16.5) with a 
minimum score of 2.5 and a maximum score of 78.9. Twenty percent of patients had 
a total score ≥ 35, which falls above the 90th percentile of overall disability in 
functioning according to general population data for the WHODAS 2.0 interview 
version (225). 
Multiple regression analyses showed no difference in the distribution of WHODAS 
2.0 scores according to age or gender.  
Re-analysis of the outcomes, excluding the two questionnaires filled out by family 
members, did not change the results. 
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Functioning and psychopathology 
The correlations between psychopathological symptoms as measured by the BPRS 




Functioning and medication side effects 
The correlations between SHRS, BARS, SWN-20, and BMI scores with WHODAS 2.0 
scores are shown in Table 2. The results indicate that a higher level of drug-induced 
parkinsonism was associated with more problems in functioning in the areas 
understanding and communicating, getting around and household activities. 
Higher well-being under neuroleptics is associated with better functioning in the 
domain of understanding and communicating.  
 
Functioning and quality of life 
The correlations between the EQ-5D and WHODAS 2.0 scores are shown in Table 2. 
A higher WHODAS 2.0 score (worse global functioning) is associated with a higher 
EQ-5D score (lower quality of life).  
 
 




This study is one of the first to examine WHODAS 2.0 proxy scores of psychosocial 
functioning in patients with SMI. Our results show that symptom severity and 
medication side effects have a negative association with functioning, quality of life, 
and subjective well-being in patients with SMI. They also recorded the highest scores 
on WHODAS 2.0 domains related to interactions with other people and participating 
in society, revealing their greater psychosocial disabilities in these areas. These 
results are consistent with earlier findings, in which psychotic patients reported 




The correlation between psychopathology symptoms and participation in society 
confirms earlier findings in SMI populations, in which patients with more severe 
psychopathology reported more difficulties in functioning on the WHODAS 2.0 (12- 
and 36-item versions), whereas patients with fewer mental health problems reported 
better scores for recovery (75,216,230). We did not find a significant correlation 
between psychosocial functioning and positive symptoms; this is in agreement with 
an earlier study in patients with schizophrenia, which found no relationship between 
positive symptoms and social network size (231). It suggests that the primary focus 
of traditional treatment on symptoms like hallucinations and thought disorders is 
not necessarily associated with better functioning.  
 
Treatment setting 
In contrast to our expectations, outpatients reported more problems with 
participation in society than inpatients. This contrasts with results from a previous 
validation study of patients with schizophrenia, in which outpatients demonstrated 
better social functioning than inpatients, as rated by independent assessors (232). 
There are several possible explanations: first, inpatients may have better participatory 
skills than outpatients. This seems unlikely however, because their psychopathology 
symptoms did not differ. Another explanation stems from healthcare professionals 
perhaps having different frames of reference for in- and outpatients and their 
participation in society. For outpatients they may have other insights into barriers for 
functioning (e.g. stigmatization) in society. It is possible that long- and short-term 
inpatients and their healthcare professionals are accustomed to the status quo and 
have lower expectations of life than outpatients (and their healthcare professionals) 
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who are constantly confronted with their disabilities when trying to operate in 
society.  
The third, and in our opinion the most plausible, explanation is that participation is 
easier in the sheltered environment of an inpatient setting, in which co-citizens also 
have severe mental disorders, and where social activities are organized, patients are 
encouraged to participate in activities, basic life needs are taken care of, and barriers 
and problems are partly resolved by caregivers. 
 
Medication side effects  
There was a significant correlation between drug-induced parkinsonism and 
problems in getting around and performing household activities. This could be 
related to the symptoms of drug-induced parkinsonism such as tremor, bradykinesia, 
rigidity and postural instability (233). These motor symptoms can directly influence 
walking pattern and daily household tasks (234,235). In addition, there was a 
significant correlation between parkinsonism and understanding and 
communicating. This is in line with earlier reports about the non-motor signs of drug-
induced parkinsonism e.g. cognitive dysfunction, apathy and mood disorders (236–
238). Hence, drug-induced parkinsonism appears to be associated with a broad 
spectrum of dysfunction and may be a barrier to recovery. 
 
Strengths and limitations 
We studied a difficult-to-examine population of severely ill psychiatric patients who 
were recruited from all three psychiatric institutions on Curaçao. There was no 
selection regarding the type of psychiatric care or medication, presence of side 
effects, or treatment response when the participants were recruited. This resulted in 
a group of patients who are representative of the general population with SMI on 
Curaçao. Although nearly half of our participants were unable to communicate in 
Dutch, we were able to use the official Dutch translation of the WHODAS 2.0, as all 
the healthcare professionals are educated in Dutch. So far, no local-language 
versions of the WHODAS 2.0 are available for populations in the Caribbean who do 
not speak English or Dutch. Although it would have been valuable to interview a 
relative, most of the patients did not have an engaged relative. A personal healthcare 
provider who was engaged with all the patient’s personal activities was interviewed 
instead. In a previous study assessing patient functioning, it was found that high-
contact clinicians generated ratings of everyday functioning that were more closely 
linked to patients’ ability scores than those from friends or relatives (239). 
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Not all patients were able to read the Dutch language. To be able to administer the 
SWN-20 self-report questionnaire to these patients, it was translated by a bilingual 
(Papiamentu-Dutch) resident-in-psychiatry. No back translation was performed and 
we did not formally ensure whether the validity and reliability of the questionnaire 
were still intact. Failure to complete back translation of the SWN-20 might have 
affected the reliability and validity of the data from the questionnaire and its 
subsequent correlation with the WHODAS 2.0 and its domains. Our examination of 
the correlation between the WHODAS 2.0 and its domains and the SWN-20 in the 
subset of patients who completed the Dutch version of the scale (n=38) showed 
similar results to those on the subset that completed the translated version of the 
SWN-20 (n=39). This indicates that the negative impact of the failure to back 
translate was minimal.  
Problems with using questionnaires on functioning with patients with poor insight 
and cognitive deficits, as reported in earlier studies and confirmed in a pilot study, 
were parried by using the proxy-version with well-informed third parties. A limitation 
of this study is that we did not interview the patients themselves using the WHODAS 
2.0, because a pilot study with the patient version of the questionnaire showed that 
patients’ concentration problems negatively affected the reliability of their answers. 
Therefore we could not compare the information given by patients with that from 
their proxies. 
Responder bias (judgment differences between healthcare professionals attending 
inpatients vs. outpatients) could not be ruled out, however, the results indicate that 
useful information on psychosocial functioning can be retrieved from proxies. 
Lastly, both the small sample size and the non-normal distribution of our data, 
requiring non-parametric tests, are challenges for the power of our analyses, and 
thus the strength of our findings. Non-parametric tests (here: Spearman rho and 
Mann Whitney) have less statistical power than their parametrical equivalents. As our 
main purpose was to explore relationships between different measures, we chose to 
show all individual results of our small sample size study. Thus, together with the fact 
that the study has a cross-sectional design, the results need to be treated with 
caution. Future studies, using larger sample sizes are needed to confirm our findings. 
 
Conclusions 
In this exploratory study, we show that the proxy version of the WHODAS 2.0 is a 
clinically useful instrument for patients with severe mental illness and that it provides 
good insight into the psychosocial functioning of these patients. In patients with lack 
of insight into their disease or severe cognitive deficits, this proxy questionnaire 
version can be used to determine useful information about patients’ problems in 
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psychosocial functioning. The highest scores on the WHODAS 2.0 (i.e., indicating the 
greatest difficulties in functioning) were found in domains related to interactions with 
other people and participation in society. Inpatients were reported to experience 
fewer problems with participation in society than outpatients, which could be due to 
the adapted circumstances and sheltered environment of the clinic. We found drug-
induced parkinsonism is associated with a broad spectrum of social disabilities. 
Before any practice or policy recommendations can be made, our results need to be 
replicated, preferably with larger samples. Wherever possible, researchers should 
include the patient interview version of the WHODAS 2.0 in order to compare the 
outcomes of the two versions of the questionnaire. 
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meaningful life in the community. Central to the monitoring of the recovery process 
is the measurement of psychosocial functioning, for which DSM-5 recommends the 
use of the WHODAS 2.0. This instrument has been shown to give valuable insight 
into patients’ experiences, but it is difficult to use with patients with long-term 
psychotic disorders because of their lack of insight (i.e., awareness of their illness and 
its consequences) and cognitive deficits. We show that the proxy version of the 
WHODAS 2.0 can parry these limitations and that it is a clinically useful instrument 
to measure psychosocial functioning in patients with severe mental illness. In our 
study population, the highest scores on the WHODAS 2.0 were found in domains 
related to interactions with other people and to participation in society. Inpatients 
appeared to have fewer problems with participation in society; this could be due to 
their living in a sheltered clinical environment and the associated daily activities. We 
further found that drug-induced parkinsonism was associated with a broad spectrum 
of psychosocial disabilities. 
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Summary of main findings  
In chapter 1 we introduced CYP enzymes. The effect of most medication is 
determined by the rate at which it is metabolized by CYP enzymes in the liver.  
In psychiatry, CYP2D6 and CYP2C19 are the most important enzymes. A combination 
of functional and non-functional alleles is responsible for the activity of these 
enzymes. There are four phenotype groups: poor (PM), intermediate (IM), normal 
(NM) (previously referred to as ‘extensive’), and ultrarapid metabolizers (UM), which 
are used to predict whether and how well a drug is metabolized. In this thesis, I have 
attempted to bridge the outcomes of pharmacogenetic studies with psychiatric 
clinical practice. The aims and outlines of the different studies in this thesis were 
described and explained. 
In chapter 2 we reviewed the literature about the prevalence of CYP2D6 and 
CYP2C19 in different ethnicities worldwide. We translated the predicted phenotypes 
into a probability estimate of having a non-normal metabolizer status, defined by 
the prevalence of PM + IM + UM in percentages. The mean probability estimates 
worldwide are 36.4% for CYP2D6 and 61.9% for CYP2C19, with a very large 
geographical variation (min-max 2.7-61.2% for CYP2D6 and 31.7-80.1% for 
CYP2C19). This means that more than half of the world population has a non-normal 
CYP2D6 and/or CYP2C19 metabolizer phenotype. The world maps show the 
geographical regions and countries for which information is available, but also 
highlight the regions with little or no information, especially in Africa and the Middle 
East. 
In chapter 3 we assessed the prevalence of CYP2D6 and CYP2C19 genotypes in 
psychiatric patients and in the general population of Dutch Caribbean origin. 
Arawak’s were the native inhabitants of Curaçao. In 1499, Spanish Europeans 
colonized the island and brought in slaves from West Africa. Immigrants from Latin 
America and other Caribbean islands came in after slavery was abolished and 
admixed with the local inhabitants (179). We investigated the impact of this 
admixture of ancestors on their allele composition and we analyzed if there were 
differences between psychiatric patients and the general population. In total, 435 
individuals were genotyped for CYP2D6 and CYP2C19. No differences in the 
prevalence of alleles was found between the general population and psychiatric 
patients. The prevalence of CYP2D6 predicted phenotypes is PM = 5%, IM = 32%, 
NM = 61% and UM = 2%, and of CYP2C19 predicted phenotypes PM = 2%, IM = 
27%, NM = 40% and UM = 31%. This distribution is in fact very similar to that seen 
in Europeans (188). 
In chapter 4 we tested the hypothesis that dose adjustment to the CYP2D6 
phenotype in patients with severe mental illness (SMI) can reduce side effects and 
improve treatment outcomes in slow metabolizers. If this is true, we would expect 
Chapter 6  
100 
 
better psychosocial functioning and an increase in quality of life. Of the 269 patients 
with SMI who were genotyped, we selected all those with a non-normal metabolizer 
profile and using psychiatric medication metabolized by CYP2D6 (n = 45); 12 of the 
45 patients were defined as PMs because they were on CYP2D6 inhibiting 
medication. We compared them with 45 patients with a normal metabolizer profile. 
Four months after dose adjustments, patients were examined on the same 
parameters. Not one of the patients of the dose adjustment group improved in 
symptoms, side effects, global functioning or quality of life. Six patients deteriorated 
of whom two patients had to be admitted to the psychiatric hospital because of 
psychotic decompensation. High maintenance doses, irreversibility of side effects 
and adaptation of the brain to the changed dopamine levels, are possible 
explanations for the absence of an effect.  
In chapter 5 we administered the WHODAS 2.0 proxy-administered version in 77 
caregivers of patients with SMI so that we could investigate its relationship with 
psychiatric symptoms, place of treatment, and side effects. The highest scores on the 
WHODAS 2.0 are found in domains related to interactions with other people and 
participation in society. Contrary to our expectations, inpatient status appeared to 
protect patients in their participation/activities in society. This could be because the 
sheltered environment of a clinic and the associated adjustments in daily activities 
makes participating in the local society easier. 
In patients with a lack of disease insight or severe cognitive deficits, this proxy version 








After the introduction of antipsychotics and antidepressants in the 1950s, the 
effectivity of these drugs was demonstrated in numerous double-blind controlled 
trials (240,241). However, antipsychotics and antidepressants produce several side 
effects, especially in patients with severe mental illness, who are prescribed these 
drugs for years and who often have severe side effects. Because there is a wide 
variability in individual response to standard doses of these drugs, finding the right 
drug type and dose is a challenging task for the clinician and can take months or 
even years (6). Pharmacogenetic testing of individual patients for CYP2D6 and 
CYP2C19 (referred to here as CYP genotyping) could offer more insight into the 
optimal drug type and dose they require for a good treatment response.  
Currently, therapeutic drugs monitoring (TDM) is used to analyze if a dose 
prescription results in the desired serum level in the blood. It can be argued that 
genotyping is superior to TDM because it gives a life-long insight into metabolization 
of medication. However, other factors that can also influence serum levels, are not 
assessed with genotyping. 
So far there has been no conclusive evidence that CYP genotyping is beneficial for 
clinical outcomes. Pharmacokinetic studies have shown the influence of the CYP2D6 
enzyme on serum levels of medication (23,242,243), while relationships between 
clinical parameters and CYP2D6 activity have also been investigated (21,244,245). 
Based on these studies, pharmacogenetic guidelines now advise adjusting the dose 
or changing the medication to fit the phenotype (44,139,246). However there is only 
scarce evidence to show improvement in clinical outcomes after genotyping 
(6,27,87). There is, therefore, an urgent need for conclusive advice on using CYP 
genotyping in psychiatry. In this thesis, we have tried to bridge the gap between the 
evidence from pharmacogenetic studies and clinical psychiatric practice. We have 
shown there is a huge variation in phenotypes in different ethnicities, which might 
explain differences in patients’ response to medication. We found, however, no 
evidence for the clinical relevance of CYP genotyping in patients with severe mental 
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CYP genotyping and clinicians 
 
“What do I have to do with this?!” 
 
This was the reply from a general practitioner (GP) on receiving the laboratory result 
with a patient’s CYP2D6 and CYP2C19 profile. When we correctly informed 
pharmacies and GPs about their patients’ phenotype (92), it became clear that not 
all GPs were able to use this information. We informed 132 GPs about their patients’ 
phenotype and after one year we asked if they had adjusted treatment to the 
phenotype. Only 4 (3%) responded and they had not used the information. This is in 
line with a 2017 study in the Netherlands that found genotyping results were 
available to GPs for only 3.1% of the genotyped patients and at pharmacies for 5.9% 
of their patients (92). In 2014, few psychiatrists were ordering a pharmacogenetic test 
(91). However, one study on patients with schizophrenia found positive effects of 
genotyping on their physician’s opinion regarding the patient’s clinical status 
(although there was no evidence of improvement of side effects) (89). In 2018 the 
FDA cautioned that there may be a lack of clinical evidence supporting the utility of 
clinical pharmacogenetic testing. Although this statement was not agreed on by 
professionals investigating CYP genotyping in clinical practice (247). 
At the start of this PhD project in 2014, it seemed that CYP genotyping was not being 
adopted in standard psychiatric care and was dependent on the individual 
preference of the clinician. Until now routine pharmacogenetic testing has not been 
translated into psychiatric practice (248,249). 
 
Prevalences of CYP2D6 and CYP2C19 worldwide 
A review of the literature in 2019 showed that a large percentage of the world 
population does not has a normal metabolizer phenotype. In chapter 2 we 
introduced the concept of a probability estimate for having a non-normal 
phenotype, as defined by the total prevalence of PM+IM+UM. Worldwide, the 
probability estimates of non-normal metabolizers are 36.4% for CYP2D6 and 61.9% 
for CYP2C19. There is also a large geographical variation in the prevalences of 
CYP2D6 (2.7-61.2%) and CYP2C19 (31.7-80.1%). The Mozabite people in Algeria, for 
example, have a 61% chance of having a non-normal metabolizer phenotype; it is 
therefore not appropriate to start with them on the same dose of an antipsychotic 
or antidepressant as a patient from Peru who has a relatively low chance (13%) of 
having a non-normal phenotype (10). Since 50-70% of antidepressants and 
antipsychotics are metabolized by one of these CYP enzymes, regular dosing 
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guidelines will not apply to most patients 
(https://www.gipdatabank.nl/servicepagina/open-data) (3,4). The observed variation 
of genotypes between ethnicities worldwide strongly suggests that pre-emptive CYP 
genotyping should be performed for every patient who will need therapy involving 
drugs that are metabolized by CYP2D6 and/or CYP2C19 enzymes. 
 
Prevalences of CYP2D6 and CYP2C19 on Curaçao 
In one study, we looked in detail at the Caribbean island of Curaçao, part of the 
former Netherlands Antilles, and where the population is a mix between native 
inhabitants, immigrants and descendants of former African slaves. Earlier studies 
there showed that psychiatric patients were vulnerable for developing side effects 
such as movements disorders and metabolic syndrome (8,65). We hypothesized that 
this vulnerability might be explained by a higher prevalence of slow medication 
metabolizers in the population. We therefore determined the prevalences of CYP2D6 
and CYP2C19 genotypes on the island and, indeed, found a completely different 
allele composition than in Europeans, although the translation into predicted 
phenotypes showed an almost similar distribution between the two groups. These 
findings imply that, in the Netherlands, the same attention should be paid to altered 
drug metabolism in immigrant families from the former Netherlands Antilles as is 
paid to Europeans in clinical practice. Our results also suggested that the inhabitants 
of Curaçao are mainly an admixture of Europeans and Sub-Saharan Africans, with 
much less input from Asians.  
In addition to the role of its polymorphisms in drug metabolism, it has also been 
suggested that CYP2D6 contributes to the susceptibility for schizophrenia, because 
of its role in the biotransformation of tyramine to dopamine (162). In a recent 
genome-wide association study, CYP2D6 expression was mentioned as a possible 
risk factor in the development of schizophrenia (250). In our study, we found no 
differences in CYP2D6 allele frequencies between psychiatric patients and the 
general island population. There is no evidence that CYP2D6 biotransformation of 
tyramine into dopamine actually increases susceptibility for schizophrenia. One 
explanation could be that studies that found lower percentages of poor metabolizers 
(PM) in patients with schizophrenia might have compared a selected inpatient group 
with healthy outpatient volunteers, which biased the results (67). In our study, almost 
30% of our psychiatric population were outpatients, so the chances of bias were 
lower. Moreover, because our control group was from the same mixed ethnic 
background, our results were not affected by ethnic differences. We found no poor 
metabolizers of CYP2C19 in the psychiatric patients, in contrast to 4.1% in the 
volunteers from the general Antillean population. But because the *2 allele, which 
causes the PM phenotype (*2/*2), was equally prevalent in both groups (14.7% vs. 
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16.2%, p = 0.595), we think this finding is coincidental. The absence of poor 
metabolizers of CYP2C19 has also been reported in Panamanian Indian and Mexican 
populations (182,183). The Indian heritage in the Netherlands Antilles could explain 
the low prevalence of CYP2C19 PM among our subjects. There is no convincing 
relationship between CYP2C19 and psychiatric symptoms (46).  
 
Analyzing functioning in patients with SMI using WHODAS 2.0 
While investigating the prevalence of CYP genotypes in the population of Curaçao, 
we also assessed the psychosocial functioning of those patients with severe mental 
illness (SMI). For years, treatment of psychiatric patients with severe psychiatric 
disorders has focused on their symptoms. The main treatment aim was remission of 
psychotic symptoms and behavioral problems. This approach is, however, not 
necessarily associated with better disease outcomes over time, since symptomatic 
remission is only partly connected to social functioning and quality of life (251). In 
recent years, treatment has focused on recovery, in which the most important goal 
is to regain a meaningful life in the community, including being able to participate 
in worthwhile activities and fulfilling social roles (205–208). We assessed the 
psychosocial functioning of patients with SMI using the World Health Organization 
Disability Assessment Schedule (WHODAS 2.0)(252).  
Contrary to our expectations, we found that inpatients had fewer problems in 
participating in society than outpatients. We suggest being in the sheltered 
environment of a psychiatric hospital, with its associated adjustments in daily 
activities, may encourage participation in society. For example, nurses wake patients 
as part of their daily routine and help them attend creative and social activities 
organized by the hospital. Inpatients know each other and are mutually tolerant.  
Another possibility is that inpatients and their healthcare professionals are 
accustomed to the status quo and may have lower expectations from life than 
outpatients (and their healthcare professionals) who are constantly confronted with 
their disabilities when in contact with society. These different frames of reference 
could partly explain the higher level of disfunction amongst outpatients. 
Another important finding was the relationship between side effects and 
psychosocial functioning. Particularly drug-induced parkinsonism was associated 
with a broad spectrum of psychosocial disabilities, such as getting around and 
performing household activities. This is good reason for psychiatrists to pay more 
attention to the effect of adjusting dose to the CYP2D6 phenotype, in patients with 
parkinsonism. 
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Effectivity of CYP2D6 genotyping 
In our patients with SMI on Curaçao, we also planned to investigate the effectivity of 
CYP genotyping on treatment outcomes. At the start of the project, we intended to 
evaluate dose adjustments to the CYP2C19 phenotype as well. Although about 60% 
of our patients had a non-normal CYP2C19 predicted phenotype, we were not able 
to include any in our study who needed a dose adjustment according to the 
guidelines (there were no patients with a non-normal CYP2C19 phenotype using 
medication metabolized by the CYP2C19 enzyme). CYP2C19 genotyping therefore 
had no added value in this group. In other populations, where patients are mainly 
prescribed medication metabolized by the CYP2C19 enzyme, genotyping may well 
predict response in certain individuals, but it is not yet clear if this will translate to 
better clinical outcomes (253). 
Before we could make dose adjustments to the CYP2D6 phenotype, we had to find 
out if psychiatrists had already adjusted doses because of side effects or treatment 
resistance. By recalculating the medication doses to a Defined Daily Dose (DDD), we 
found that the average DDD in the whole group was 1.68 (SD 0.92). There was no 
correlation between the predicted phenotypes and the prescribed dose of 
antipsychotics (Figure 2, chapter 4), PMs, IMs and UMs were prescribed the same 
amounts of psychopharmacological medication as the NMs, even when we only 
included antipsychotics metabolized by the CYP2D6 enzyme. We even found higher 
doses of antipsychotic medication in slow metabolizers (PM 1.86 (SD 1.21) vs. UM 
1.12 (SD 0.44), p = 0.16) (Figure 2, chapter 4), and again when we analyzed the DDD 
of medication metabolized by the CYP2D6 enzyme.  
In a Russian study of inpatients with schizophrenia, there were also no differences 
found in mean dose of antipsychotic medication between the CYP2D6 metabolizer 
groups with an average DDD ~ 1.7 (254). In a Swedish study, significantly lower doses 
of antipsychotics were found in PM- than EM outpatients. This could be due to a 
lower average prescribed DDD in this group of patients (DDD = 0.6), which would 
make any differences in the effects of medication more clear than in patients on 
higher doses (255).  
When we compared the in- and outpatients in our population, we found a DDD = 
1.8 in the inpatient group versus a DDD = 1.2 in the outpatient group (p<0.001). In 
the outpatient group, we did not find a correlation between CYP2D6 activity level 
and DDD. Apparently, the clinical differences seen in tardive dyskinesia and 
parkinsonism are not large enough to stimulate psychiatrists to adjust dose to an 
individual phenotype. Our results also confirmed this: we found no differences in 
drug-induced movement disorders nor in metabolic parameters between the 
different metabolizer groups. Thus, it is even more important to study whether CYP 
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genotyping and medication adjustments actually result in better treatment 
outcomes.  
Many antipsychotics, especially those metabolized by CYP2D6 (haloperidol, 
aripiprazole and risperidone) have bell-shaped dose-response curves, which means 
that treatment response decreases if the dose is are higher than optimal (256). With 
these types of antipsychotics, PMs automatically have a higher chance of being 
prescribed a dose above the optimal one for them and therefore a lower treatment 
response. Also, higher plasma levels of antipsychotic medication show lower levels 
of subjective wellbeing in patients with schizophrenia (257). Positron emission 
tomography (PET) studies showed that when dopamine 2 receptor occupancy 
exceeds 78%, the likelihood of extra pyramidal symptoms is significantly increased, 
whereas an occupancy between 60-70% is optimal in patients with schizophrenia 
(41,157). It could be that doses were far above the 78% occupancy even after dose 
reduction and that might explain why we found no differences in symptoms between 
the two groups (Figure 1). Some studies found differences in tardive dyskinesia and 
parkinsonism between patients with a normal (NM) and a reduced metabolism (PM 
+ IM). Patients in these studies were also taking antipsychotic medication long term, 
but again in significantly lower doses (DDD = 0.3-1) (43,160,258,259).  
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Figure 1.  Schematic adaptations of the dose concentration relationship, after a single dose of 




DDD= Defined Daily Dose, c=concentration of drugs in blood, t=time in hours 
 
Most of the studies on movements disorders between metabolizer groups were 
underpowered and the results did not reach significant difference. When the results 
were pooled in a meta-analysis, the differences in severity of drug-induced 
movement disorders were considered too small to be clinically meaningful (OR = 
1.24) (27,160,258–260). We also found no differences at the start of our study, nor a 
trend toward improvement after dose adjustment. Even in a subanalysis of 16 
patients using small doses (DDD ≤ 1.0), we saw no improvements in the intervention 
group. This supports the idea that differences in movements disorders between 
Dose plasmaconcentration curve in a NM with a DDD=1 
Dose plasmaconcentration curve in a PM with a DDD=1 
Dose plasmaconcentration curve in a PM with a DDD=1.7 
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metabolizer groups are too small to be demonstrated in small clinical trials or in 
clinical practice. 
Another explanation for the lack of effect from CYP genotyping on psychiatric 
symptoms or side effects could be that long-term use of antipsychotics induces 
structural changes in the brain (132). In a review, the process of sensitization and 
tolerance to antipsychotics was proposed to explain why clinical trials fail to 
demonstrate efficacy of novel treatments (261); and chronic use of antipsychotics 
induced changes in neuroplasticity and the patient’s brain became sensitive to 
antipsychotic medication (262). Sensitization leads to increased behavioral side 
effects. A prior antipsychotic treatment history and subsequent withdrawal because 
of dose adjustment could cause a ‘supersensitivity psychosis’, i.e. a drug-induced 
psychotic relapse following an interruption of chronic antipsychotic treatment. The 
drug-induced increase in the mesolimbic dopamine postsynaptic D2 (high) 
receptors, which has been shown in animal models, is suggested to be the underlying 
mechanism (263). A Japanese study has shown a higher prevalence of 
supersensitivity psychosis in CYP2D6 poor metabolizers, although the results did not 
reach significance. They hypothesized that a higher risperidone concentration in PMs 
leads to a higher risk of this type of psychosis (264). The supersensitivity psychosis 
might explain the deterioration of some patients after dose adjustment in our study 
sample (n = 6).  
Liu and Takeuchi have recently proposed an algorithm for dose reduction of 
antipsychotics with only a fraction (no more than 25%) of the dose to be reduced at 
any time, and with at least a 6-month stabilization period to prevent psychotic 
decompensation (265). This is in marked contrast with the 50% dose reduction, taken 
in two steps over 4 months, we adopted in our study setting. 
More support for this sensitivity hypothesis is that drug-induced movement 
disorders are not as reversible as initially thought. Earlier studies reported that only 
3% of patients who discontinued the drugs causing their movement disorder showed 
improvement in tardive syndromes (133). A lower dose of antipsychotics did not 
decrease the severity of parkinsonism in patients with SMI on high doses (66). In this 
clinical population, perhaps a dose adjustment to match their CYP2D6 phenotype 
would have had an effect in an earlier phase of treatment, but the years had led to 
irreversible neuroplastic changes.  
When we searched the literature, we found most of the studies reporting potential 
clinical benefits from CYP genotyping were observational; they found extreme 
metabolizers had longer stays in psychiatric hospital (5,42,138,266). We found only 
three prospective studies that reported an effect of CYP genotyping on side effects 
for patients with schizophrenia with non-normal CYP2D6 metabolizer profiles 
(7,43,254). There were two differences between these studies and our study. First, in 
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two studies reporting on the average dose of antipsychotics, the average DDD was 
around 1 compared with DDD = 1.68 in our population. Second, in all three studies, 
patients were selected for CYP genotyping when there was an intention to start 
antipsychotic treatment or to switch drug type, and clinical reasoning was part of the 
decision to adopt genotype-guided treatment. In the study by Herbild et al., for 
example, there was only the additional information on the patient’s genotype and a 
recommendation to adjust the pharmacological treatment accordingly, but the 
decision adjust the dose was left to the clinician. Our study was different in the timing 
and instructions on dose adjustment: there was no clinical reason to genotype the 
patients and the dose reductions were purely guided by genotype and not by the 
patient’s clinical symptoms. Many of the patients in our study who received 
adjustments were already relatively stable on their dose regimes, although their 
doses were high, they were suffering from diverse side effects, and many were 
admitted to psychiatric wards for chronically ill patients. 
This means that in other studies finding an effect of CYP genotyping, there was 
already a clinical reason or intention to change from standard dosing regimens. 
These patients were not stable on their dosing regimens or were suffering from so 
many side effects that they had already requested a change in medication. In our 
study, every patient’s dose was adjusted, clinical symptoms were not taken into 
account. We excluded only those patients who were unwilling to have their dose 
adjusted (n = 3). It is possible that a selected group of patients who do not respond 
on standard treatment regimes would see more benefit from genotype-guided 
treatment. This could be revealed when there is a reassessment of the standard 
treatment and/or when clinical pros and cons are being carefully weighed. The large 
group of patients who benefit from standard treatment without too many side effects 
would not necessarily benefit more from genotype-guided treatment and dose 
adjustments. In 15% (6/45) of the patients we investigated adjusting the dose even 
caused their condition to deteriorate. 
 
Pharmacokinetics 
The majority of evidence for CYP genotyping in pharmaceutical guidelines comes 
from studies on the relationship between CYP activity and the plasma concentrations 
of psychiatric medication (267–269). The relationship between the plasma 
concentration of antipsychotic medication and clinical outcomes is a topic of 
ongoing debate. For example, some studies found no correlation between plasma 
concentration of active moiety and clinical efficacy of risperidone (270,271). 
We were able to measure the plasma levels of haloperidol, zuclopenthixol and 
risperidone in 31 patients at the start of the study. Only for risperidone was there a 
moderate correlation between metabolic activity and plasma level (Pearson 
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correlation coefficient -0.5; p = 0.08) (with higher plasma levels in PMs than in NMs 
and UMs). This is in line with another study that found a correlation between 
risperidone concentration and CYP2D6 activity (272). However, it is in contrast with 
studies in natural cohorts of patients with schizophrenia that found correlations 
between haloperidol and zuclopenthixol plasma levels and CYP2D6 activity (22,258). 
It should be noted that, in those studies, body weight and smoking were equally 
important determinants of haloperidol clearance. 
 
Conclusions 
Since 1988, more than 3000 papers on CYP2D6 and/or CYP2C19 have been 
published. Probability estimates of a person having a non-normal metabolizer profile 
show that about 36.4% (CYP2D6) and 61.9% (CYP2C19) of the world population has 
a non-normal metabolism, which suggests that genotyping may be highly relevant 
to clinical practice. This is supported by pharmacokinetic studies. However, these 
studies have mostly been conducted by pharmacologists and pharmacogeneticists, 
and they do not offer translation of genotyping results to clinical practice. This thesis 
has attempted to bridge the gap between the evidence from pharmacogenetic 
studies and psychiatric practice.  
The majority of the evidence for current treatment guidelines comes from studies on 
the relationship between CYP activity and plasma levels of psychiatric medication 
(267–269). Although plasma levels are clinically relevant, the ‘proof of the pudding’ 
is if genotype-guided treatment results in more effectivity and/or fewer or less severe 
side effects. 
Studies showing trends in clinical validity in patients with SMI are often 
underpowered. Patient groups on lower doses of antipsychotics seem to benefit the 
most from genotype-guided treatment. There is also some evidence that CYP2D6 
and CYP2C19 genotyping, as additional information next to clinical considerations, 
can benefit treatment outcomes (psychopathology and side effects). 
Although it might appear that genotyping is without risk, our study of 45 patients 
showed that six deteriorated after their dose was adjusted, including two who had 
to be admitted to a psychiatric hospital because of psychotic decompensation.  
It could be that in patients on years of antipsychotic treatment, following genotyping 
guidelines without carefully considering clinical symptoms and side effects, will do 
more harm than good.  
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Directions for further research  
The results of this thesis call for modesty regarding the benefits of genotyping in 
patients with severe mental illness. Future studies should focus on the clinical utility 
of CYP genotyping in psychiatric practice. First, patients with SMI have often been 
using antipsychotic medication for several years. Irreversible neuroplastic changes in 
the brain might explain the negative results for CYP genotyping in our study. It is 
therefore necessary to study if genotyping should be used at an earlier phase of the 
disorder, in patients without a medication history. It might even prevent the 
development toward SMI. Future studies should be performed prospectively and 
focus on patients with a first psychotic episode, with a blank or short history of 
antipsychotic use.  
Second, studies providing evidence for cost effectiveness show that differences 
between metabolizer groups only become significant when patients using 
medication not metabolized by CYP2D6 are excluded from the analysis (42). Studies 
also easily become underpowered when patients with a normal metabolizer 
phenotype are included in the analysis (7). This means that to be able to estimate 
effects of routine CYP2D6 genotyping, the studies should include large numbers of 
patients using medications metabolized by CYP2D6.  
In the Netherlands, antipsychotics metabolized by CYP2D6 (haloperidol, risperidone, 
aripiprazole and zuclopenthixol) form 41% of that medication prescribed 
(https://www.gipdatabank.nl/servicepagina/open-data)(2017). In about 36% (PM + 
IM+ UM) of these patients (273), the Royal Association for the Advancement of 
Pharmacy would advise adjusting the dose to phenotype (44,85). Thus, if all patients 
using antipsychotics are genotyped for CYP2D6, around 15% (0.41*0.36) of them may 
benefit from dose adjustment. This means that about seven patients have to be 
genotyped for one patient to benefit from genotype-guided dose adjustments in 
one patient, or in other words, the number to screen is seven. 
Large randomized controlled trials are therefore needed. Confounders such as 
inhibiting medication, treatment adherence, drug and alcohol use, and inflammation 
should be considered and drug-plasma levels should be measured. When evaluating 
the outcomes, the focus should not only be on primary disease symptoms and side 
effects, but also on recovery of function. In patients with cognitive deficits or lack of 
disease insight, the WHODAS 2.0 proxy version proved to be a powerful clinical 
instrument.  
Lastly, research on genotype frequencies should focus on regions that are under-
investigated such as the Middle East and Africa. When individuals are included in a 
study, their ethnicity must be well defined, preferably by confirming three 
generations of lineage. Most importantly, a minimum number of alleles and 
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duplications must be investigated to avoid overestimation of the wildtype/normal 
phenotype. 
This thesis shows there are many studies that hold value for clinical practice, but the 
field would benefit from much more communication between the disciplines to make 
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According to the global burden of disease studies, about 16% of the global 
population is suffering from a mental disorder or addiction (274). A considerable 
amount of these patients uses antipsychotic or antidepressant medication. Mental 
disorders cause considerable burden of disease, in 2016 globally, 162.5 million 
Disability Adjusted Life Years (DALYs) were lost due to mental or addictive disorders, 
about 7% of all DALYs lost by disease (274). 
In 2017, almost 1.5 million people in the Netherlands, were prescribed an 
antidepressant or antipsychotic drug 
 (https://www.gipdatabank.nl/servicepagina/open-data). Unfortunately, many of 
these patients discontinue their treatment because of in-effectivity of the treatment 
or life-influencing side effects (1,240,241). Patients with SMI, with a long history of 
antidepressant or antipsychotic drugs, are especially known to suffer from problems 
with adverse drug reactions and lack of medication effect (1,69,70). Side-effects can 
impair psychosocial functioning and may influence the quality of life (1,186). There is 
a need for tools which enhance effectivity and lower the risk on side-effects of 
pharmacological treatment.  
Of specific interest are the activity of the CYP2D6 and CYP2C19 enzymes because 
about 50-75% of all antidepressant and antipsychotic drugs is metabolized by either 
one of these enzymes (https://www.gipdatabank.nl/servicepagina/open-data) 
(29,275). There are studies showing that the activity of the CYP2D6 and the CYP2C19 
enzymes is related to the prevalence of side effects and treatment response (6,22). 
Also, the costs of treatment and length of hospitalization of poor metabolizers (PMs) 
and ultrarapid metabolizers (UMs) are on average, longer than of intermediate 
metabolizers (IMs) and normal metabolizers (NMs) (5,42). In a cost analysis study in 
patients with schizophrenia in Denmark, overall health costs were found to be 177% 
higher in all extreme metabolizers (PM + UM) compared to NMs and that genotyping 
could lead to lower treatment costs (7). A study in patients with schizophrenia 
showed that patients receiving pharmacogenetic testing prior to a switch or start of 
antipsychotics showed some improvement in side effects compared to the patients 
receiving treatment as usual, even though effects were minimal and not significant 
(43). It is hypothesized that CYP genotyping can lead to better treatment outcomes 
and reduced treatment costs (7).  
Precision or personalized medicine may optimize treatment decisions by a tailor-
made strategy for each individual patient. Pharmacogenetic testing is becoming 
more and more available and prices of testing are dropping (276). A genetic test for 
CYP2D6 and CYP2C19 costs about €260 in an academic hospital in the Netherlands 
(Erasmus Mc Rotterdam). It is becoming available for a bigger public and 
psychiatrists are encouraged to perform pharmacogenetic testing. In some hospitals, 
testing is routine practice, while in others pharmacogenetic testing is seldom done. 




Pharmacy available with instruction how to handle with the outcomes of a genetic 
test, but there are still some issues to address before implementing it in clinical 
practice. 
First, there is a lack of communication between test manufacturers and clinicians, 
which is required to narrow the gap between the availability and implementation of 
these tests in psychiatric practice (276). Second, there is still no consensus under 
psychiatrists if genotyping is (cost) effective and which patient groups could benefit 
from this diagnostic tool.  
This thesis aimed to narrow the gap between evidence from pharmacogenetic 
studies and clinical psychiatric practice. It is intended to facilitate the clinical working 
doctor (general practitioners, psychiatrists and all medical doctors prescribing 
antidepressants or antipsychotics), especially those working with patients with SMI. 
We investigated the probability of having a non-normal phenotype in different 
ethnicities and analyzed whether CYP genotyping could yield better treatment 
outcomes (psychopathology, side-effects and functioning) for patients with Severe 
Mental Illness.  
In this thesis we introduced a new term: ‘non-normal probability estimate’. 
Introducing this term to the field of pharmacogenomics made it possible to see 
which ethnicities are at the highest risk for developing dose dependent side effects 
or treatment failure. The information is presented in world maps, and for the first 
time it is visualized which world areas are under investigated and have to be focus 
of research. The prevalence of non-normal CYP2D6 and CYP2C19 phenotypes for the 
different ethnicities are gathered in two world maps, which is an important step in a 
globalizing world and may be especially helpful in the treatment of migrants. 
We found that 36% of the world population is having a non-normal CYP2D6 
phenotype and that 62% is having a non-normal CYP2C19 phenotype. We know now, 
that to come to a reliable test outcome, one should minimally genotype alleles, that 
are prevalent in the specific geographic region a patient is from. In inhabitants from 
the former Netherlands Antilles the same attention should be paid to altered drug 
clearance, as is paid to Europeans.  
Also, we conclude that for patients with SMI on years of antipsychotic treatment, 
CYP2D6 genotyping is not effective. CYP genotyping did not show any effects on 
side-effects, psychopathology, functioning or quality of life. Pre-existent high 
maintenance dosages, irreversibility of side effects and adaptation of the brain to 
years of D2 receptor antagonism, are possible explanations why genotyping in this 
population did not show a beneficial effect on one of these parameters. This study is 
suggesting that routine genotyping in this patient population is not effective and 
urges to modesty in genotyping. This insight saves us from needless diagnostic 
testing and pseudo-certainty about medication effects. Although it seems that, 
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besides extra costs, genotyping is without risk, our study showed that six patients 
deteriorated after dose adjustment and even two patients had to be admitted in 
psychiatric hospital because of psychotic decompensation. When following 
genotyping guidelines without carefully considering clinical symptoms and side 
effects it could be that genotype guided treatment will do more harm than good. It 
is highly necessary to study if genotyping in an earlier phase of the disorder, in 
patients without a long medication history, may be beneficial in terms of 
effectiveness and side effect profile. 
Lastly, we found that the proxy version of the WHODAS 2.0 is a useful instrument for 
measuring functioning when patients are not able to complete the questionnaire 
themselves.  
The results of the thesis have been published in four scientific journals, of which three 
are in open access journals and one journal which supplies the article to membered 
universities or after payment. To inform a broader public of clinicians working in the 
Netherlands, an article in Dutch will be written and will be submitted to The Journal 
of Psychiatry.  
Individual test outcomes were communicated to general practitioners and 
pharmacists in the Netherlands and to the psychiatrists at Curaçao. Wherever there 
were questions about the relevance or practical implications of the test outcomes, 
they were answered according to the latest scientific knowledge. Findings from the 
studies were presented at diverse congresses and symposia worldwide. The 
committee that is writing the Dutch guideline Pharmacogenetics in Psychiatry 
personally have been informed of the results of the study that shows that routine 
genotyping in patients with SMI did not show any beneficial effects. Table 1 is 
summarizing where the research for this thesis was presented. In these meetings, 
clinicians, fellow researchers and policy makers were informed about the latest 
results and invited to discuss the possible benefits from genotyping in clinical 
practice.  
Results of the meta-analysis about worldwide prevalence of CYP2D6 and CYP2C19 
phenotypes and the non-normal probability estimates, are freely available for a 
bigger public on the website www.ethnopsychopharmacology.com. This website is 
an initiative from Prof. M. Braakman and is a platform for scientific data about 






Table 1. Congresses at which (preliminary) findings of this thesis were presented 
DATE MEETING TYPE PLACE 
2014  
 
ZonMw Diversity congress  oral presentation The Hague, the 
Netherlands 
2014 Educational presentation for doctors 
in training to psychiatrist, Parnassia 
Group The Hague 




Congress of Dutch Caribbean 
foundation for clinical higher 
education (NASKHO)  
workshop Willemstad, Curaçao 
2015 
  
Research day of School for Mental 
Health & Neuroscience Research 













2017 European Conference of 
Schizophrenia Research (ECSR) 
workshop Berlin, Germany 
2018 Congress of Dutch Association for 
Psychiatry (NVvP) 
workshop Maastricht, the 
Netherlands 
2018 American Psychiatric Association 
(APA) Research Program 
oral presentation+ 
poster presentation 
New York, USA 
2019 Scientific-Educational program of 
Education Consortium  
Parnassia-LUMC-Rivierduinen 
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De enzymen CYP2D6 en CYP2C19, werkzaam in de lever, spelen een belangrijk rol in 
de afbraak van bijna alle antipsychotica en antidepressiva. CYP2D6 is 
verantwoordelijk voor de afbraak van o.a. haloperidol, aripiprazol, risperidon, 
amitriptyline en nortriptyline (29). CYP2C19 o.a. voor de afbraak van citalopram, 
sertraline en clomipramine (29). Er zijn allerlei factoren van invloed op de snelheid 
waarmee deze enzymen medicatie afbreken, bijvoorbeeld het gebruik van alcohol, 
drugs, sigaretten, medicatie en ook voeding, zwangerschap of infecties (14–19). Eén 
van de belangrijkste factoren is echter de manier waarop het enzym gecodeerd is in 
het DNA, ook wel het polymorfisme genoemd. Elk enzym wordt gecodeerd door 
twee allelen en afhankelijk van het aantal actieve allelen kan het genotype vertaald 
worden naar een fenotype. De fenotypen van CYP2D6 en CYP2C19 worden ingedeeld 
in vier groepen: trage metaboliseerders (PM), intermediaire metaboliseerders (IM), 
normale metaboliseerders (NM, voorheen EM) en ultrasnelle metaboliseerders (UM) 
(33). Een snel CYP2D6 en/of CYP2C19 metabolisme leidt bij een normale dosering 
tot een lagere dan gemiddelde spiegel van het medicament en veelal tot 
verminderde effectiviteit omdat het medicijn sneller uit het lichaam verwijderd wordt 
en dus minder lang werkzaam is. Terwijl een langzaam metabolisme bij een normale 
dosering leidt tot een hogere dan gemiddelde spiegel en vaak tot meer 
(dosisafhankelijke) bijwerkingen (20–25). Naast verhoogde gevoeligheid voor 
bijwerkingen is er ook een verband aangetoond tussen een vertraagd fenotype en 
hogere zorgkosten (7,42). Snelle metaboliseerders bleven achteraf gezien langer 
opgenomen in het ziekenhuis omdat het langer duurde voordat ze goed waren 
ingesteld op medicatie (5,42,138,266) . Richtlijnen adviseren om dosisaanpassingen 
te doen bij patiënten met een PM, IM of UM-fenotype om een optimaal effect te 
bewerkstellingen en bijwerkingen terug te dringen. Het is echter niet duidelijk of het 
bepalen van CYP2D6 en CYP2C19 in de praktijk ook leidt tot meer effectiviteit en 
minder bijwerkingen. Er is veel discussie in de recente literatuur of we nu juist wel of 
niet vaker moeten genotyperen (2,277,278). In 2018 ging er zelfs een waarschuwing 
uit van de FDA (Food and Drug Administration) dat er onvoldoende evidentie was 
voor het op grote schaal klinisch toepassen van CYP genotypering (247). Het is dus 
belangrijk om hier meer duidelijkheid over te krijgen. 
Prevalentie van de verschillende allelen en dus ook de fenotypen verschillen sterk 
per etniciteit. Bijvoorbeeld, in Europese populaties is de prevalentie van CYP2D6 UM 
3% in vergelijking tot 20-29% in Afrikaanse populaties (11,81). CYP2C19 PMs komen 
vaker voor in Azië (12%) dan in Europa (2%) (82). In hoofdstuk 2, hebben wij 
onderzocht hoe vaak de deze fenotypen wereldwijd voorkomen en welke etniciteiten 
de grootste kans hebben op een niet-normaal fenotype. De kans op een niet-
normaal fenotype is gedefinieerd als de prevalentie van PM + IM + UM. We konden 




kans op een niet-normaal CYP2D6 fenotype 36% en een niet normaal CYP2C19 
fenotype 62% is. Dit betekent dat meer dan de helft van de wereldbevolking een 
niet-normaal CYP2D6 en/of CYP2C19 fenotype heeft. De kansen op een niet-normaal 
fenotype hebben we weergegeven in wereldkaarten. Op die manier is ook duidelijk 
geworden dat er met name in Afrika en het Midden-Oosten nog weinig prevalentie 
onderzoek gedaan is. 
Het eiland Curaçao, onderdeel van de voormalige Nederlandse Antillen, heeft een 
populatie met een diverse genetische achtergrond. Het grootste deel van de 
bewoners stamt af van de slaven uit West-Afrika. Er is verder vermenging met de 
inheemse Indiaanse populatie en er zijn Chinezen, Europeanen en Zuid-Amerikanen 
naar het eiland gemigreerd. Deze bijzondere combinatie aan afstammelingen heeft 
geleid tot een bevolkingsgroep met een eigen unieke DNA-samenstelling. Het is 
echter nog onbekend wat de prevalentie is van de CYP2D6 en CYP2C19 fenotypen. 
In sommige populaties in de Latijns-Amerikaanse regio is de prevalentie van PMs 
extreem hoog (10%). Daarnaast is het aantal psychiatrische patiënten dat last heeft 
van bijwerkingen hoog. Zo werd in eerdere studie (The Curaçao Extrapyramidal 
Symptoms Study) aangetoond dat door medicatie-geïnduceerde 
bewegingsstoornissen vaak voorkomen en soms heftig verlopen (8). Voorbeelden 
van dit soort bewegingsstoornissen zijn: parkinsonisme, (combinatie van tremor, 
bewegingsarmoede en rigiditeit), dyskinesie (onwillekeurige spierbewegingen) en 
acathisie (bewegingsonrust). Zou het mogelijk zijn om dit soort bijwerkingen te 
verminderen als we de medicatie aan zouden passen aan de CYP fenotypen? 
In hoofdstuk 3 hebben wij onderzocht hoe vaak de fenotypen voorkomen op 
Curaçao. De onderzochte groep bestond uit een 269 psychiatrische patiënten op 
Curaçao en 166 mensen uit de algemene bevolking afkomstig van Curaçao 
woonachtig in Nederland. De prevalentie van de CYP2D6 fenotypen zijn als volgt: 
PM = 5%, IM = 32%, NM = 61% en UM = 2%. De prevalentie van de CYP2C19 
fenotypen zijn PM = 2%, IM = 27%, NM = 40% en UM = 31%. Deze prevalenties 
blijken zeer vergelijkbaar met die van Europeanen. Er zijn geen verschillen in 
prevalentie tussen psychiatrische patiënten en niet-psychiatrische vrijwilligers 
gevonden.  
In hoofdstuk 4 hebben we onderzocht of het bepalen van de genotypen van 
CYP2D6 en CYP2C19 zinvol kan zijn bij patiënten met ernstige psychiatrische 
aandoeningen (EPA).  
Om de effectiviteit van CYP2D6 en CYP2C19 genotypering in patiënten met EPA te 
onderzoeken hebben we uit de groep van 269 patiënten waarvan we het genotype 
bepaald hadden, alle patiënten geselecteerd met een niet-normaal CYP2D6 en/of 
CYP2C19 fenotype en medicatie gebruik door het betreffende metaboliserende 




een dosis aanpassing nodig hadden op basis van hun fenotype. Zij werden gematcht 
met een controlegroep van 41 NM-patiënten. Alle 45 patiënten werden geselecteerd 
vanwege een dosisaanpassing op basis van het CYP2D6 profiel, er waren geen 
patiënten met een niet-normaal CYP2C19 fenotype en medicatie gemetaboliseerd 
door CYP2C19. De patiënten werden vóór en vier maanden na de dosisaanpassing 
gemeten op psychopathologie, metabole bijwerkingen en bewegingsstoornissen, 
sociaal functioneren en kwaliteit van leven. Bij aanvang van de studie werd geen 
verschil in gemiddelde-dosering-voorgeschreven-antipsychotica tussen de 
verschillende fenotypen gevonden. Blijkbaar deden artsen geen aanpassing naar het 
fenotype op basis van klinische verschillen, mogelijk omdat de verschillen klinisch 
onvoldoende zichtbaar waren. Er waren geen verschillen in psychopathologie, 
bijwerkingen, het functioneren en kwaliteit van leven tussen de dosisaanpassing- en 
de controlegroep vóór en na de dosisverandering. Wij hebben hieruit geconcludeerd 
dat dosisaanpassing op basis van CYP2D6 fenotype geen effectieve interventie is in 
psychiatrische patiënten reeds langdurig ingesteld op antipsychotica. We hebben 
hiervoor verschillende mogelijke verklaringen.  
Allereerst denken we dat langdurig antipsychotica leidt tot adaptatie aan veranderde 
dopamineconcentraties waardoor chronisch gebruik leidt tot structurele 
veranderingen in breinvolume, dopamine-2 en serotonine receptor concentratie en 
verhoogde affiniteit van de dopaminereceptor voor endogeen dopamine 
(132,261,262). Er zijn studies die laten zien dat bewegingsstoornissen als gevolg van 
langdurig antipsychotica gebruik niet in remissie gaan als de medicatie in dosering 
verlaagd of gestaakt wordt, terwijl dit wel altijd verondersteld werd (66,133). Tevens 
zijn er aanwijzingen voor het controversiële idee dat chronische blootstelling aan 
antipsychotica leidt tot verhoogde gevoeligheid voor psychose (262). Deze 
verhoogde gevoeligheid wordt ook wel het ‘Dopamine Supersensitiviteit Syndroom’ 
genoemd (261,263). Bij afbouwen van medicatie kan er een 
‘supersensitiviteitspsychose’ ontstaan als gevolg van supergevoelige dopamine 2 
receptoren die zonder antipsychotica direct ontregelen. Dit mechanisme zou 
verklaren waarom een groot gedeelte (n = 6) van de patiënten die een 
dosisaanpassingen hadden gekregen decompenseerde na dosisaanpassing. 
Een tweede verklaring voor het uitblijven van effect van dosisaanpassing, is dat 
patiënten relatief hoge doseringen antipsychotica gebruikten (DDD = 1.68). Mogelijk 
is dit ook gerelateerd aan de veronderstelling dat sensitiviteit voor dopamine vraagt 
om steeds verdere verhoging van de dosering om psychose te voorkomen. Eerder is 
in onderzoek aangetoond dat er boven een bepaalde dopamine D2 receptor 
bezetting een aanzienlijk grotere kans is op bewegingsstoornissen (41). De kans is 
groot dat de patiënten die dosisaanpassing hebben gekregen nog steeds ver boven 
die bezettingsgraad zaten waardoor de dosisverlaging geen invloed heeft gehad op 




Dit betekent dat in de dagelijkse klinische praktijk bij patiënten reeds ingesteld op 
antipsychotica, CYP2D6 genotypering vooralsnog geen routinematige interventie 
hoeft te worden. Omdat het uitblijven van een effect voor een belangrijk deel 
verklaard wordt door het feit dat patiënten reeds ingesteld waren op medicatie, 
zouden wij toekomstige onderzoekers adviseren zich te richten op patiënten zonder 
medicatievoorgeschiedenis.  
Wij hebben in hoofdstuk 5 onderzocht, of de WHODAS 2.0 proxy-versie (World 
Health Organization Disability Assessment Score) waardevolle informatie kan geven 
over het functioneren van patiënten met ernstige psychiatrische aandoeningen. De 
WHODAS 2.0 is opgenomen in de DSM-5 ter vervanging van de GAF (Global 
Assessment of Functioning), het is een vragenlijst die is ontwikkeld om ziekte en 
cultuur overstijgend te meten hoeveel last mensen hebben van een aandoening in 
het dagelijks leven (211). Patiënten met ernstige psychiatrische aandoeningen 
(schizofrenie, bipolaire stoornis, ernstige depressieve stoornis) hebben echter vaak 
last van cognitieve stoornissen waardoor het soms moeite kost de aandacht bij de 
vragenlijsten te houden (75,76,216). Soms zorgt beperkt ziekte-inzicht tot andere 
uitkomsten dan wordt ingeschat door behandelaren of naasten. Wij hebben bij 77 
verzorgers van patiënten met EPA deze vragenlijst afgenomen en een goed beeld 
gekregen van het functioneren van deze patiënten. De hoogste scores voor 
disfunctioneren werden gevonden in de domeinen die gingen over interacties met 
andere mensen en deelname van de samenleving. Tegen onze verwachting in 
vonden wij dat opgenomen patiënten minder moeite hadden met deelname aan de 
samenleving dan ambulante patiënten. Een verklaring zou kunnen zijn dat de 
samenleving waarin de opgenomen patiënten deelnemen beschermd is en dat 
dagelijkse activiteiten aangepast zijn aan de mate van disfunctioneren waardoor 
deelname relatief makkelijk is. Het zou echter ook zo kunnen zijn dat verzorgenden 
van opgenomen patiënten een ander referentiekader gebruiken dan verzorgenden 
van ambulante patiënten. Een andere belangrijke bevinding was dat de bijwerking 
parkinsonisme geassocieerd is met een breedspectrum van disfunctioneren zoals 
rondlopen en uitvoeren van huishoudelijke taken.  
Concluderend, vonden wij dat wereldwijd de kans op een niet-normaal CYP2D6 
fenotype 36% en een niet normaal CYP2C19 fenotype 62% is. Dit betekent dat meer 
dan de helft van de wereldbevolking een niet-normaal CYP2D6 en/of CYP2C19 
fenotype heeft. Dosisaanpassing op basis van fenotype bij patiënten reeds 
langdurige ingesteld op antipsychotica, op het eiland Curaçao is echter niet zinvol 
gebleken. Terwijl de verdeling van de fenotypen bij bewoners van Curaçao, zeer 
vergelijkbaar is met die van gezonde vrijwilligers en met de verdeling van fenotypen 
onder Europeanen. De proxy-versie van de WHODAS 2.0, opgenomen in de DSM-5 
ter vervanging van de GAF, is een klinisch bruikbaar instrument om functioneren te 




Aanbevelingen voor de toekomst  
Hoewel er multipele studies zijn, die het verband aantonen tussen CYP enzymen en 
de hoogte van de bloedspiegel van een medicament, zijn er slechts enkele studies 
die onderzoek hebben gedaan naar het effect van genotypering op klinische 
uitkomsten. Het grotendeel van de studies bij patiënten met antipsychotica gebruik 
zijn observationeel, retrospectief en hebben kleine patiënten aantallen. In Nederland 
wordt ongeveer 40% van de voorgeschreven antipsychotica (haloperidol, 
risperidone, aripiprazole en zuclopenthixol) gemetaboliseerd door CYP2D6. In 
ongeveer 36% (PM + IM+ UM) van deze patiënten adviseert de KNMP een 
dosisaanpassing. Dit betekent dat 15% (0.41 * 0.36) van alle patiënten die gebruik 
maken van antipsychotica zouden kunnen profiteren van genotypering. Of te wel een 
‘number needed to screen’ van 7. 
Toekomstig onderzoek zou zich met behulp van een prospectief design, moeten 
richten op het effect van genotypering op behandeleffecten en bijwerkingen bij 
patiënten met een eerste psychotische episode die geen of een korte 



















ABC =  Aruba Bonaire Curaçao  
ANCOVA = Analysis of Covariance 
ANOVA = Analysis of Variance  
BARS = Barnes Rating Scale for drug-induced akathisia 
BMI = Body Mass Index   
BPRS = Brief Psychiatric Rating Scale 
CEIBA = cocktail of caffeine, omeprazole, dextromethorphan and losartan   
CPIC = Clinical pharmacogenetics implementation consortium  
CYP2C19 = Cytochrome P450 2C19, member of the CYP2C subfamily  
CYP2D6 = Cytochrome P450 2D6, member of the CYP2C subfamily 
CYP450 = Cytochrome P450 
DALY = Disability Adjusted Life Years 
DDD = Defined Daily Dose   
DNA = Deoxyribonucleic acid  
DPWG = Dutch Pharmacogenetics Working Group  
DSM-5 = Diagnostic and Statistical Manual of mental disorders  
EM = Extensive Metabolizer  
EPA = Ernstige Psychiatrische Aandoeningen 
Eq5D = EQol 5-D 
FDA = Food and Drug Administration  
GAF = Global Assessment of Functioning 
HWE = Hardy Weinberg Equilibrium  
IM = Intermediate Metabolizer 
KNMP = Koninklijke Maatschappij ter bevordering der Pharmacie 




NVvP= Nederlandse Vereniging voor Psychiatrie  
PM = Poor Metabolizer   
SAMSHA = Substance Abuse and Mental Health Services Administration  
SD = Standard Deviation 
SHRS = St. Hans Rating Scale 
SMI = Severe Mental Illness 
SWN-20 = Subjective Well-being under Neuroleptics scale 
TCA = Tricyclic Antidepressant 
TDM = Therapeutic Drug Monitoring  
UM = Ultrarapid Metabolizer 
WHO = World Health Organization 
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Supplemental Table 2. References of Table 3 - Chapter 2 
Africa  
African (22) 
African (north and East) (15) 
Biaka, Pygmies (Subsaharan Africa) (3) 
Colored (South African) (21,29) 
Esan (Nigerian) (20) 
Gambian (20) 
Luhya in Webuye (Kenian) (20) 
Mandenka (Subsaharan Africa) (3) 
Mende (Sierra Leonean) (20) 
Mozabite (Algerian) (3) 
North African (2) 
South African (1) 
West African (2) 
Xhosa (South African) (25) 
Yoruba (Nigerian) (Ibadan) (20) 







Admixed Latin Americans (22,81) 
African Caribbean (Barbados) (20) 
African Caribbean from Barbados (Costa Rica) (301) 
Afro-Latin Americans (81) 
American Indian (84) 
Brazilian (North East) (76) 
Brazilian (North) (76) 
Brazilian (South East) (76) 
Brazilian (South) (76) 
Brazilian from African descent (302) 
Brazilian from Caucasian descent (302) 
Central Native Americans (81) 
Colombian (20,54) 
Coras (Mexican) (83) 




Dutch Caribbean (69) 
Ecuadorian (63,72) 
Huicholes (Mexican) (83) 
Iberians (81) 
Indo-Trinidad (301) 
Jewish (Ashkenazi) (81) 
Karitiana (South American) (3) 
Lacandones (Mexican) (77) 
Maya (Mexican) (83) 
Maya (South American) (3) 
Mestizo (Cuban) (303) 
Mestizo (Mexican) (44,67,77) 
Mestizo (Nicarguan) (58,303) 
Mexican (20,53,68,83) 
North Native Americans (81) 
Peruvian (20) 
Pima (South American) (3) 
Puerto Rican (20) 
South American (2) 
South Native Americans (81) 
Surui (South American) (3) 
Tarahumares (Mexican) (83) 
Tepehuanos (Mexican) (83) 
White Latin Americans (81) 
  
Central/ South East Asia  
Balochi (Central/South Asia) (3) 
Bengali (20) 
Brahui (Central/South Asia) (3) 
Burusho (Central/South Asia) (3) 
Gujarati (Indian) (20) 
Hazara (Central/South Asia) (3) 
Kalash (Central/South Asia) (3) 
Makrani (Central/South Asia) (3) 
Pathan (Central/South Asia) (3) 
Punjabi (Indian) (20) 




South Asian (2,22) 
South East Asia (2) 
Tamil (Sri Lankan) (20) 
Telugu (Indian) (20) 
Uyghurs (Central/South Asia) (3) 
Viet Kinh (Vietnamese) (20) 
Western India (101) 
  
East Asia  
Chinese (96,131,132) 
Dai (Chinese) (20) 
East Asian (22) 
Han (Chinese) (20,87,129,142) 
Han (East Asia) (3) 
Japanese (3,20,131,136,161) 
Shanghai (Chinese) (132) 
Shantou (Chinese) (132) 
Shenyang (Chinese) (132) 
South Korean (127,131,138,184) 
Tibetan Chinese (121) 
Xi’an (Chinese) (132) 
Yakut (East Asia) (3) 
  
Europe  
Basque (French) (3) 
British (20) 
Caucasian (Danish) (201) 
Caucasian (European) (22,260) 
Caucasian (Hungarian) (217) 
Caucasian (USA) (20,230) 
Estonian (259) 
Finnish (20) 
Finnish (East) (101) 
Finnish (West) (101) 
French (3) 
German (191) 




Jewish (Ashkenazi) (260) 
Lithuania  (256) 
Ravenna Italian (15) 
Roma (Italian) (2) 
Russian (3) 
Sardinian (Italian) (3) 
Spanish (248) 
Toscani (Italian) (20) 
  
Middle East  
Arabian Bedouins (Israel) (266) 
Bedouin (Middle Eastern) (3) 
Druze (Middle Eastern) (3) 
Jewish (Israel) (266) 
Palestinian (Westbank) (3) 
  
Oceania  
Aboriginal (North West Australia) (299) 











Cape Mixed Ancestry (South African) (23) 
Tzotziles (Ugandese) (27) 
Xhosa (South African) (23) 
  
African American (30)(32) 
  
Americas  
Admixed Latin Americans (22) 
African Caribbeans from Barbados (Costa Rica) (71) 
Brazilian (43) 
Bribri (Costa Rican) (71) 
Costa Rican (71) 
Dutch Caribbean (69) 
Ecuadorian (72) 
Guarani (Brazil) (65) 
Guaymi (Costa Rican) (71) 
Mestizo (Costa Rican) (71) 
Mestizo (Ecuadorian) (62) 
Mestizo (Mexican) (73) 
Mexican (68,80) 
  
Central/ South East Asia  
Buruhi (Pakistani) (113) 
Burushu (Pakistani) (113) 
Hazara (Pakistani) (113) 
Indian (West) (118) 
Kalash (Pakistani) (113) 
Koya (Indian) (107) 
Naik (Indian) (107) 
Pakistani (111,116) 
Parsi (Pakistani) (113) 
Pathan (Pakistani) (113) 




Saraiki (Pakistani) (113) 
Sindhi (Pakistani) (113) 
South Asian (22) 
Tamil (Indian) (South) (119) 
  
East Asia  
Bai (Chinese) (145) 
Chinese (31,57,93,131) 
East Asian (22,24,32,34) 
Hakka (Chinese) (182) 
Han (Chinese) (120,123,124,128,129,145,177) 
Han (Chinese) (North) (154) 
Han (Chinese) (South) (154) 
Han (Taiwanese) (139) 
Hui (Chinese) (123,124) 
Japanese (24) 
Japanese (31,48,131,133,135,140,144,146,165,169,170) 
Kazakh (Chinese) (128) 
Li (Chinese) (162,176) 
Mongolian (123,124,158) 
Shanghai (Chinese) (130) 
Shantou (Chinese) (130) 
Shenyang (Chinese) (130) 
South Korean (24,90,122,125,126,131,147,159) 
Tibetan Chinese (173) 
Tohoku (Japanese) (165) 
Uyghurs (Chinese) (124,128,179) 
Xi’an (Chinese) (130) 
  
Europe  
Avars (Russian) (245) 
Caucasian (European) (22,131,260) 
Caucasian (USA) (30,32) 
Danish (221) 






Finnish (North) (254) 
Greek (196) 
Hispanic (USA) (30,32) 
Jewish (30) 
Jewish (Ashkenazi) (190,260) 
Jewish (Sephardi) (190) 
Laks (Russian) (245) 
Macedonian (187) 
Nanai (Russian) (246) 
Norwegian (221) 
Scandinavian (221) 
Spanish (North) (62) 
Swedish (125) 
  
Middle East  
Caspian (Iranian) (304) 
Fars (Iranian) (304) 
Iranian (286,289) 
Kurd (Iranian) (304) 
Lure (Iranian) (304) 
Saoudi Arabian (271,292) 













This supplemental material belongs to Chapter 2. It is available as electronic 
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Wijbrand Hoek, als belangrijke schakel in het contact tussen de psychiatrische 
praktijk van Curaçao en Nederland, was jij vanaf het begin bij dit project betrokken. 
Je deed me als mijn aanstaand opleider het aanbod om naar Curaçao te gaan. Voor 
mij een lot uit de loterij! Ik kon weer terug naar het eiland waar ik een jaar eerder 
met veel plezier gewerkt had, en dat in combinatie met de opleiding tot psychiater. 
Ik geloof niet dat ik het beter kon treffen. Deze bijzondere combinatie, helemaal 
passend bij mijn persoonlijke situatie kenmerkt jouw stijl van begeleiden en opleiden. 
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dag samen naar school waardoor we elkaar nogal goed hebben leren kennen. 
Ondanks een flinke fysieke afstand (Utrecht-Maastricht) voel jij nog steeds feilloos 
aan hoe het leven er bij mij voorstaat. Ik hou van je gezelligheid en je optimistische 
kijk op het leven, als ik van iemand heb geleerd wat doorzetten is dan ben jij het wel! 
Dan mijn lieve, slimme zusjes Merel, Marleen en Kristijn, op de één of andere manier 
hebben we alle vier een ongebreidelde interesse in het brein. Toen we klein waren 
trokken we elkaar de haren uit het hoofd maar inmiddels kunnen we niet zonder 
elkaar. Ik voel me door jullie ontzettend gesteund en geliefd. Merel, na zoveel jaren 
als zussen ben ik steeds minder grote en jij steeds minder kleine zus en dat is fijn. Ik 
ben heel erg blij dat je me als paranimf op mijn promotie kan bijstaan. Ik weet zeker 
dat als ik flauwval, je me tot de tand toe zal verdedigen!  
Mijn ouders, Ben en Liesbeth, aan jullie heb ik een heel warm nest te danken met alle 




komen waar ik wil zijn. Nog steeds kan ik jou opbellen voor advies en ben je altijd 
een luisterend oor. Mam, ook jij bent er in voor en tegenspoed. Je bent een krachtig 
en zorgzaam mens en hierin een voorbeeld voor mij.   
En dan tot slot, mijn eigen lieve jonge gezinnetje. Mijn dierbare Jos, alweer 14 jaar 
samen, ik denk dat ik hier niet gekomen was zonder jou. Allereerst omdat jij voor mij 
een inspiratiebron bent geweest om te beginnen met het onderzoek. Ik heb veel aan 
je gehad tijdens het gehele proces, onder andere doordat jij het allemaal al een keer 
doorlopen had. Maar vooral omdat er met jouw creativiteitstheorie overal een 
oplossing voor is. Jij bent de kalmte zelve en bij jou ben ik mezelf. Je zou een hele 
goede psychiater kunnen zijn, maar gelukkig ben je het niet!  
Lieve Ise en lieve Kees, jullie zijn een stel deugnieten! Jullie hebben het me eigenlijk 
alleen maar moeilijker gemaakt en daar ben ik jullie dankbaar voor. Door jullie weet 
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